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Abbreviations 
Ad Adamantane 
AMOX  Amoxicillin  
AZT-MP Azidothimidine monophosphate  
AZT-TP Azidothimidine triphosphate  
BET Brunauer, Emmett and Teller 
BHI  Brain Heart Infusion 
BTC    1,3,5 benzene tricarboxylate 
Bz Benzophenone  
CAP   Captopril  
CD-MOFs Cyclodextrin-based metal organic frameworks 
CD-NPs  Cyclodextrin-based nanoparticles  
CD-P    β-CD-phosphates  
CDs Cyclodextrins  
CFU/mL   Colony forming units per milliliter  
CL   Clavulanate potassium 
CT Computed Tomography  
CTAB Cetyl trimethylammonium bromide  
CUS   Coordinatively unsaturated metal sites 
DCM   Dichloromethane  
Dex Dextran 
Dex-Ad    Dex bearing adamantane (Ad) side units 
Dex-Bz Dex bearing Bz side units  
Dex-C12 Dextran (Dex) grafted with alkyl side chains 
DL   Drug loading  
DLS   Dynamic light scattering 
DMF N,N-Dimethylformamide  
D-γ-CD   Dual-γ-CD unit  
EE   The encapsulation efficiency  
EP   Epichlorohydrin  
EtOH   Ethanol  
FA Ferulic acid  
FBS   Fetal bovine serum 
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GCMC   Grand Canonical Monte Carlo  
Gem-MP Gemcitabine-monophosphate  
HPAC   High Performance Affinity Chromatography 
HPLC  High Performance Liquid Chromatograph 
IBU Ibuprofen 
iPrOH  Isopropanol 
IRMOF-3 Isoreticular metal organic frameworks 
KOH   Potassium hydroxide 
LDH  Lactate dehydrogenase leakage  
LGA   Lamarckian Genetic Algorithm  
LiCl   Lithium chloride 
LPZ   Lansoprazole  
MD   Molecular dynamics  
Me2CO   Acetone  
MeOH   Methanol  
MIL Materials of Institut Lavoisier 
MOFs Metal-organic frameworks 
MRI Magnetic resonance imaging  
MS   Materials Studio 
MSNs Mesoporous silica nanoparticles  
MTT   3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl tetrazolium bromide 
nanoMOFs   nano-scaled MOFs  
NaOH Sodium hydroxide    
NPs Nanoparticles  
NTA   Nanoparticle tracking analysis  
PAA Polyacrylic acid 
PBS   Phosphate buffer saline  
PdI   Polydispersity  
poly-CD CD polymer  
RAFT Reversible addition−fragmentation chain transfer  
RI Refractive index  
RITC Rhodamine B isothiocyanate  
S. Aureus   Staphylococcus aureus 
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SEC  Size exclusion chromatography  
SEM   Scanning electron microscopy  
TEM   Transmission electron microscopy  
TGA  Thermogravimetric analysis  
TL  Theoretical loading  
TPT Topotecan  
TTBB   1,3,5-tri-tert-butylbenzene  
TTMOFs Tumor targeting MOFs  
XRD   X-ray Diffraction 
XRDP   X-ray diffraction patterns 
Y Yield of NPs 
ZP   Zeta potential  
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General Introduction 
Pharmacy has evolved regarding the specific needs of the patient. In the last five decades, the 
development of pharmaceutical carriers allowed the formulations to protect the fragile drugs 
from degradation, reduce the side effects of drugs together with allowing controlled drug release 
and targeted delivery 1–5. Among all the drug delivery systems, “cage” particles recently drew 
special attention since they could act as “drug containers” which potentially load large amount 
of drugs, improve the stability of the drugs, and co-encapsulate synergetic drugs 6–8. 
Cyclodextrins (CDs) are typical “cage” molecules due to their truncated cone shape with a 
hydrophobic cavity and a hydrophilic outer surface 9. These unique properties enable CDs to 
form inclusion complexes with a variety of active molecules. They have been used as “molecule 
containers” to improve the solubility and bioavailability of poorly soluble drugs, stabilize drugs 
from light, thermal, and oxidative degradation, and mask the bitter taste of the drugs 10–12. 
Therefore, self-assembled nanoparticles (NPs) composed of CDs are attractive formulations. 
However, since the cavity of the CDs is small, their loadig capacity is reduced to a number of 
drugs or portions of drugs. 
Recently, a new type of porous CD-based metal organic frameworks (CD-MOFs) was 
synthesized 13. They can be imagined as buildings built using CDs which act as hollow bricks. 
CD-MOFs contain not only the cavities of CDs, but also the big pores built up by CDs self-
assemblies (Fig.1). Compared with CD-based NPs (CD-NPs), CD-MOFs have the possibility 
to load more drug payloads. Unfortunately, these particles immediately disassemble in aqueous 
media, which limits their application for oral or intravenous administration. Surface 
modification is therefore necessary to improve their stability in water. However, the process of 
surface modification leads to larger particles and reduced drug payloads. 
Water-stable MOFs are a novel type of hybrid particles, showing a high potential as drug 
carriers. Iron trimesate MOFs, namely, MIL-100 (Fe) (MIL stands for Material of Institute 
Lavoisier) was among the first nanoscaled MOFs to be used for drug delivery14. It is a “cage” 
porous particle made of iron trimers connected by trimesic acid linkers. Because of their high 
pore volumes and surface areas, MIL-100 (Fe) particles were shown to load a large variety of 
drugs, such as antibiotics and anticancer drugs, which were able to efficiently penetrate within 
the porous MOF structures. 
Therefore, three types of particles were successfully synthesized and used for the incorporation 
of active ingredients. 
8 
 
1. CD-NP was the first investigated system in this study. The advantages of these NPs lie on 
their “green” and simple preparation procedure. They could be obtained in pure water just 
by mixing two neutral polymers which instantaneously associate together. The host–guest 
interactions leading to inclusion complexes between hydrophobic molecules and the apolar 
concavities of CDs can be exploited for the formation of stable CD-NPs. A main objective 
was to use microfluidics to automatically prepare NPs in water media. Our interest was also 
focused on developing complementary techniques to well characterize the particles by in 
situ size measurements, and individual particle tracking (chapter 2), however, the drug 
loading capacity is not high (~ 5wt%). 
2. Aiming at enhanced payload of drugs, CD-MOFs were synthesized because of their porous 
structure. Firstly, the synthesis of CD-MOFs was optimized to shorten the synthesis process 
and to obtain particles suitable as drug carriers (Chapter 3.1). Drugs of interest, such as 
lansoprazole (LPZ) were then encapsulated. Of note, methods were developed to study the 
morphology and chemical composition of individual particles (Chapter 3.2). In order to 
improve the stability of the loaded CD-MOFs in aqueous conditions and control the drug 
release, surface modification was performed (Chapter 3.3).  
3. Since the surface modification was normally complicated and could probably reduce the 
drug payloads, MIL-100 (Fe) NPs were finally used as water-stable drug carrier in this 
study. It has been shown that they interact efficiently with phosphated drugs/coatings with 
high efficiencies. To gain new insights into the complex interactions taking place in the 
MOF/drug/coating systems, we developed a method based on Raman microscopy to track 
the morphology and chemical composition of individual particles (Chapter 4.1). Aiming at 
a drug combination delivery, co-encapsulation of two synergic antibiotics (Amoxicillin and 
potassium clavulanate) was successfully acheived (Chapter 4.2). 
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Chapter 1: Introduction 
1. “Cage” molecules: CDs 
CDs were first isolated in 1891 by Villiers from the enzymatic degradation products of starch1. 
They are a family of cyclic oligosaccharides composed glucopyranose units. CDs are cage-like 
supramolecular with a hydrophilic outer surface and a hydrophobic central cavity. As a result 
of this cavity, CDs are able to form inclusion complexes with a variety of hydrophobic guest 
molecules, which can lead to advantageous changes in the chemical and physical properties of 
the included guest molecules. Therefore, CDs are widely used as "molecular cages" in the 
pharmaceutical to enhance the solubility, stability, and bioavailability of drug molecules2. They 
have been recognized as pharmaceutical excipients for the past 20 years. 
1.1 Structure and properties  
The most common natural CDs are α, β and γ-CDs, containing 6, 7 and 8 glucopyranose units 
respectively, attached by α-1,4-linkages (Fig.1). Due to the chair formation of the 
glucopyranose units, CDs are shaped like bottomless nest-shaped (truncated cone) molecules 
with primary hydroxyl groups extending from the narrow edge and the secondary groups from 
the wider edge. This makes the outer surface of CD molecules hydrophilic, whereas the 
lipophilicity of their inner cavity is comparable to an aqueous ethanolic solution 3.  
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Fig.1 Structure of α, β and γ-CDs. 
These unique molecular shape and structure allow CDs to act as a molecular container by 
trapping guest molecules in their cavity. Once the guest molecules were included, their water 
solubility, volatility, stability, bioavailability, and even the taste could be improved 4.  
The natural CDs, in particular β-CD, have limited water solubility (18.5 mg/mL, 25°C) 2, which 
often results in precipitation of the inclusion complexes from the aqueous systems. Therefore, 
functionalized CDs were synthesized, including CD derivatives, and cross-linked CD 
polymers5. They are prepared by chemical or enzymatic reactions. The main objective of 
functionalization for pharmaceutical interest are: 1) to improve the solubility of the CDs and 
their inclusion complexes; 2) to reduce the toxicity of CDs, such as the nephrotoxicity of β-CD; 
3) to improve the fitting and/or the association between the CD and its guest. 
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CD derivatives. New derivatives of CDs for pharmaceutical application were synthesized and 
currently used in pharmaceutical products, including hydroxypropyl derivatives of β-CD and γ-
CD (HP-β-CD and HP-γ-CD), sulfobutylether β-CD (SBE-β-CD), and randomly methylated β-
CD (RM-β-CD) 6,7. These CD derivatives are of very high water solubility (>500 mg/mL). The 
main reason for this significant solubility enhancement is due to the transformation of the 
crystalline forms of natural CDs into amorphous mixtures of isomeric derivatives 8.  
Moreover, hydrophilic derivatives of β-CD could be used in parenteral formulations showing 
reduced nephrotoxicity as compared to natural CDs 9. 
Cross-linked CD polymer. Recently, cross-linked CD polymers were synthesized and widely 
used in polymeric systems, such as hydrogels, nano/microparticles, and micelles, etc. Cross-
linked CD polymers were generally synthesized with cross-linker agents at controlled 
temperature 5,10. Epoxides (e.g. epichlorohydrine (EP) or glycidylethers), isocyanates, 
aldehydes, and ketones are suitable cross-linking agents for CDs 11. EP is considered as the 
most investigated agent. It posseses two reactive groups that can react with the hydroxyl groups 
of CDs or with other EP molecules under alkaline conditions. This reaction usually leads to 
microgels, which are composed of a mixture of cross-linked CDs joined by repeating glyceryl 
units of polymerized EP12. Hydrosoluble CD polymers can also be obtained if the cross-linking 
reaction is quenched at a certain stage 13. Poly-β-CD synthesized by this way draw special 
attention in polymeric self-assembled systems because of its high solubility, and high capacity 
to form inclusion complexes with guest molecules 14–16. 
1.2 Safety and biocompatibility of CDs 
The α, β and γ-CDs were well tolerated when administered orally only a small fraction absorbed 
from the gastrointestinal tract 2,7. Some CD derivatives such as HP-CD could be used safely for 
intravenous administration and were mainly excreted unchanged in the urine. However, β-CD 
showed nephrotoxicity when administered parenterally, in part, possibly due to its low aqueous 
solubility 2. Lipophilic CD derivatives, such as RM-β-CD, were absorbed to a greater extent 
from the gastrointestinal tract and induced a toxic effet after parenteral administration 17. Oral 
administration of RM-β-CD is presently limited because of its potential toxicity. 
However, it is worth mentioning that the first targeted, polymer-based nanoparticle system 
carrying siRNA to be systemically administered to humans was based on polymeric cationic 
CDs 18.  
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1.3 Inclusion complex formation based on host-guest interactions 
The inclusion complexes between CDs and guest molecules are formed mainly by hydrogen 
bonding, and van der Waals interactions. The release of enthalpy-rich water molecules from the 
CD cavity, and electrostatic interactions also contribute to the inclusion formation. As there are 
no covalent bonds, guest molecules in the complex are in equilibrium with free molecules in 
solution (Fig. 2). 
  
 
Fig. 2 The conventional inclusion complex formation when one guest molecule forms a 
complex with one CD molecule. 
The key factor for the inclusion complex formation is the thermodynamic interaction between 
the chosen CDs and the drug molecules. As shown in Fig.2, the larger the KC, the more the 
equilibrium will shift towards complex formation. There are four energetically favorable 
interactions that help increase KC 
19 : (i) the displacement of polar water molecules from the 
hydrophobic CD cavity; (ii) the increased number of hydrogen bonds formed as the displaced 
water returns to the larger pool; (iii) a reduction in the repulsive interactions between the 
hydrophobic guest and the aqueous environment; and (iv) an increase in van der Waals 
interactions and/or hydrogen bonds formation as the guest molecule inserts itself into the 
hydrophobic CD cavity. The first two interactions are similar in any case, but the last two 
interactions are up to the affinity between the guest molecule and the CD, which is dependent 
on the size, hydrophobicity and structure of both the guest molecules and the type of CDs. 
Inclusion complexes could be formed at the molar ratios of 1:1 or 1:2 between the guest 
molecule and CD (Fig.3). However, as shown in Fig. 3C, CDs are also known to form non-
inclusion complexes and complex aggregates capable of dissolving drugs through micelle-like 
structures 3. 
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Fig.3 Types of inclusion complexes formed at the molar ratio of 1:1 (A) and 1:2 (B) between 
the guest molecule and CD; Non-conventional CD complexes (C). 
1.4 CD-based drug-carriers  
CDs are widely used in drug delivery system, including hydrogels, polymeric NPs, liposomes, 
niosomes, micelles, millirods, nanosponges, and supramolecular vesicles, etc20. They were 
employed almost everywhere in the pharmaceutical field, but there are only few types of drug 
carriers mainly composed of CDs. Herein, CD-based hydrogels and NPs driven by CD inclusion 
complexes and CD-based metal organic frameworks (CD-MOFs) were introduced. 
CD-based hydrogels and NPs driven by CD inclusion complexes. 
Supramolecular structures could be formed by simply mixing poly-CDs or polymers grafted 
with CDs and polymers bearing guest groups. Both hydrogels and NPs can be obtained 
depending on the concentration of the polymers and their architecture 21 . The inclusion 
complex formed between CDs in one polymer and the guest molecules in other polymer acted 
as knots that link the lines into nets which could further assemble into NPs or hydrogels. 
The combination between β-CD-bearing polymers and adamantane (Ada)-bearing polymers 
were stable, due to their host–guest interaction (Ka ∼ 104 –105 M−1) 8,17,22. Some other guest 
molecules were also used, such as alkyl chains, cholesterol, β-benzyl L-aspartate, 
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benzimidazole, and even some hydrophobic drugs 10,22,23 . It was found that polymers grafted 
with alkyl chains could also form stable supramolecular structures, despite the relatively low 
CD-alkyl chain association constant 14. The cooperative effect of multiple complex formation 
played a major role on ensuring the stability of the edifices. 
Drugs could be loaded in different ways. As already described, some hydrophobic drugs could 
be used directly as guest molecules5. In this case, the drugs could be conjugated in CD-bearing 
polymer or in another polymer. Fig. 4 A and B show the NPs formation driven by CD-drug 
inclusion. Alternatively, drugs could be loaded after the hydrogels/NPs formation by forming 
inclusion complexes with free CDs remaining unoccupied after particle formation (Fig. 4C). 
This strategy avoids the synthesis of drug-polymer conjugate, which can be deleterious for some 
fragile drugs 24. However, the disadvantage of this type of particles lies on the low drug loading 
and the equilibrium between the free drug and included drug. When the particles were diluted, 
the equilibrium would shift to the free drug formation which leads to drug leakage.    
Fig. 4 Different models that represent how the drugs were loaded in the CD-based 
hydrogels/NPs driven by CD inclusion complexes. A, the drugs were conjugated to CD-bearing 
polymers; B, the drugs were conjugated on a different polymer; C, the drugs were loaded in 
free CDs that were not occupied by the guest molecules.  
“Cage” particles: CD-based metal organic frameworks (CD-MOFs).  
Although CDs are “cage” molecules, the cavity of the cage is very limited because of the 
dimension of the molecules. Therefore, porous “cage” particles, CD-MOFs, were recently 
synthesized in the group of Dr. Fraser Stoddart 25. CD-MOFs were formed by reacting γ-CD 
and potassium ions employing a vapor diffusion method. In the originally reported synthesis 25, 
“edible” CD-MOFs were prepared by dissolving commercially available food-grade KCl or 
potassium benzoate and food-grade γ-CD in distilled water. The aqueous solution was filtered 
through cotton wool, following vapor diffusion of grain alcohol into the solution over around 
one week. In this process, the γ-CD molecules are linked by potassium ions to form a body-
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centered cubic structure (Fig.5). They are porous particles built with cubic units which have a 
pore of 1.7 nm. CD-MOFs greatly improved the capability of CDs to encapsulate drug 
molecules26–28. 
 
Fig.5 structure of CD-MOFs 
To obtain monodispersed CD-MOFs for drug delivery, the synthesis was optimized29. It has 
been discovered that addition of cetyl trimethylammonium bromide (CTAB) leads to the 
preparation of smaller CD-MOFs (1-10 μm). If methanol was also added together with CTAB, 
nanoscale CD-MOF could be obtained (200-300 nm). All these syntheses employing vapor 
diffusion methods took long time (26-32 h). It was recently reported that nano-CD-MOFs (100-
300 nm) were successfully obtained by a microwave-assisted method in shorter time (≤ 70 min) 
30. However, the formed CD-MOFs were polydispersed. Further optimization of CD-MOFs 
synthesis is still needed for their biomedical applications. 
CD-MOFs have shown their capability to encapsulate molecules of interest, including 
ibuprofen 28, fenbufen 31, doxorubicin 32, curcumin 27, sucralose 33, ferulic acid 26, 4-
phenylazophenol and rodamine B 25. Impregnation and co-crystallization are two reported 
approaches for the incorporation. A high payload of 23−26 wt % was reached in the case of 
ibuprofen by impregnation 28. Payload of 18.5 wt % was reached for Rhodamine B by co-
crystallization 25.  
However, applications of CD-MOFs as drug carriers are severely hampered since they can be 
easily disassociated in aqueous environment. To address this issue, the first idea was to 
crosslink CDs in the framework of CD-MOFs, producing CD-MOF hydrogels 29. However, the 
cross-linking reaction required long time incubation (over three days) at controlled temperature 
(~ 65°C), which would be harmful for many of the drugs if they are already loaded. Recently, 
a facile method to improve their stability has been developed via the incorporation of 
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hydrophobic fullerene (C60) in their matrices 
32. It has been shown that C60 (0.7 nm in diameter) 
can be partially trapped within the cavity of a γ-CD, forming a CD-MOF/C60 composite. Water-
resistance of CD-MOFs could be improved since the trapped C60 endowed CD-MOFs with 
enhanced hydrophobicity. When the CD-MOF/C60 composite was immersed in water, C60 layer 
could effectively repel water molecules from contacting MOF surface, therefore, the stability 
of CD-MOFs in aqueous condition was significantly improved. This study was performed with 
very large CD-MOFs (more than 400 µm) and the sytem still needs further investigations for 
its medical application. 
2. Hybrid metal–organic framework nanoparticles (MOFs) 
MOFs are an intriguing class of hybrid materials obtained by the self-assembly of metallic ions 
or clusters and bridging organic ligands, leading to the formation of three-dimensional networks 
with high and regular porosities 34-38. Taking advantage of MOF important porous surface and 
large pore size, versatility in terms of architecture, composition and physico-chemical 
properties, they have been intensively used in the last several years for a number of different 
applications such as catalysis, separation and gas storage and more recently, in nanomedecine.  
The use of MOF materials for biomedical applications, and in particular as drug nanocarriers, 
requires MOFs to be scaled-down to the nanometer sizes 39 using essentially bottom-up 
approaches, involving controlling the MOF nucleation rate and crystallization in order to limit 
the MOF growth to submicronic sizes.  
MOFs have high porosities together with important available BET (Brunauer, Emmett and 
Teller) surface areas ranging generally from 1000 up to 7000 m2 /g 38, 40-45 higher than BET 
surface of mesoporous silica nanoparticles (MSNs), which is up to around 1200 m2 /g 46. The 
large nanoMOFs surface areas together with their peculiar inner environments (both 
hydrophilic and hydrophobic) make these materials particularly appealing for the entrapment 
of drugs. The active molecules cross the MOF windows to get adsorbed onto the inner surfaces 
and interact with metal sites and/or organic constituting ligands.  
When scaling down the synthesis to the nanometer range, the outer surface properties play an 
increasing role, as the external surface-area-to-volume ratio is increasing. Indeed, the outer 
surface properties determine the nanoMOFs’ colloidal stability and interactions with biological 
environments.  
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2.1 Strategies to scale-down MOFs to the nano-regime. 
A large variety of methods have been developed to produce MOFs with submicronic sizes 
(Fig.6). They include solvothermal methods assisted or not by microwave irradiation 47,48, 
solvent diffusion synthesis25, dry-gel conversion methods49, mechanochemical 50–52 or 
sonochemical synthesis 53, production by reverse-phase microemulsions 54–56, electrochemical 
synthesis 57, preparation using a microfluidics device 58. Besides, step-by-step 59 and high-
throughput synthesis methods 60 were developed. Whatever the process, a main challenge is to 
control the crystallization process in order to achieve particles with uniform sizes less than one 
micron. Main strategies to achieve this goal consisted in adding crystal growth inhibitors, 
speeding the crystallization process, using nanoscale templates and downsizing the particles by 
mechanical or mechano-chemical methods. 
  
Fig.6. Overview of main synthesis methods for MOFs 
Blocking or inhibiting crystal growth. Various blocking agent or acido-basic or inhibiting 
additives such as acetic acid, hydroxybenzoic acid and pyridine were added in the MOF 
synthesis to retard the nucleation growth process. For example, the size of the flexible porous 
iron muconate MIL-89 (MIL stands for Materials from Institut Lavoisier) could be reduced 
down to 30 nm by adding acetate ions in the reaction process 61. In another study, pyridine was 
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used as inhibitor in the solvothermal synthesis of porous indium terephthalate particles 62. Both 
the size and shape of the particles were affected by the inhibitor. In the absence of pyridine, 
hexagonal rods of around 1.75 μm width and 16.3 μm length were formed. Pyridine enables to 
reduce both width and diameters to 0.97 μm and 0.43 μm, respectively. 
Luminescent nanoparticles made of terbium benzenedicarboxylate with sizes of only 4-5 nm 
were successfully obtained by adapting a previous method 63 using a poly(vinilpyrrolidone) as 
inhibitor of crystal growth 64.  
Accelerating the crystallization process. An alternative methods to the use of crystal growth 
inhibitors, was to speed up the crystallization process. This strategy was applied to CD-MOFs 
prepared by solvent diffusion (Fig.6).  
The chiral γ-CDs comprise eight α-1,4-linked D-glucopyranosyl residues disposed in a 
symmetric configuration. This allows the γ-CD building units to assemble with alkali metal 
ions (K+, Na+, Rb+, and Cs+) in aqueous media to form body-centered cubic CD-MOFs (Fig. 
5). For example, K+ based CD-MOFs were obtained under the form of large particles of around 
200‒400 µm by reacting γ-CD with KOH in aqueous solution, followed by vapor diffusion of 
methanol into the solution at room temperature during 2–7 days. The addition of cetyl 
trimethylammonium bromide (CTAB) together with an optimization of the reaction conditions 
enabled to reduce the reaction times and to obtain nano-scaled CD-MOF (200-300 nm) 31. Of 
note, cubic particles with homogeneous sizes were obtained by using CTAB. 
The reaction time was found to dramatically influence the MOF size distribution. The diameters 
of Zn3(BTC)2·12H2O MOFs were reduced from 700 - 900 nm to 50 - 100 nm by decreasing the 
reaction time from 90 to around 10 min 65. 
Nanoscale templates. Another promising strategy to obtained nanoscaled MOFs was the 
synthesis in confined spaces, using a template approach. For example, Gd-based MOF66 
nanoparticles were obtained in reverse microemulsions prepared using mixtures of CTAB, 
isooctane, 1-hexanol and water. The morphology and size of nanoscale templates were 
dramatically altered by both the composition of the system and the presence of sodium 
salicylate, a hydrotrope 66-67.  
Downsizing. Nanosized MOFs were prepared mechanochemical synthesis, consisting in a 
mechanical breakage of intramolecular bonds followed by a chemical transformation. First 
examples of the synthesis of porous MOF by this method were reported in 2006 51. 
Advantageously, mechanochemical reactions can occur at room temperature under solvent-free 
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conditions 68. Nanoparticles of HKUST-1 were successfully produced in solvent free conditions 
50. Mechanochemical synthesis of MOF nanoparticles were reviewed69. More recently, 
nanosized Gd-based porous MOF has been synthesized by mechanical downsizing by ball 
milling the as-synthesized MOF with millimeter-scaled sizes.70  
All these synthesis method have led to the obtention of a large variety of materials with rigid 
or flexible structures. Examples are compiled in Fig.7.  
 
Fig.7 Overview of some representive examples of flexible and rigid of MOFs. The breathing 
MOFs: MIL-53-It (It=low temperature), MIL-53-Ibu (Ibu= Ibuprofen), and MIL-53-ht (ht=high 
temperature) are from reference 87; The swelling MOFs are from reference 45. The series 
of MIL-88 were prepared with iron trimer and different ligand: fumaric acid (MIL-88A), 
terephthalic acid (MIL-88B), 2,6-naphthalenedicarboxylic acid (MIL-88C) and 4,4′-
biphenyldicarboxylic acid (MIL-88D). 
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2.2 Drug entrapment and release    
Active molecules, mainly anticancer drugs have been successfully incorporated in the 
nanoMOFs using three main strategies schematized in Fig.8.  
The first group of MOFs considered as potential drug delivery system is the MIL family. In 
particular, MIL nanoMOFs build from trivalent metal centers and polycarboxylic acid bridging 
ligands develop outstanding surface areas (1500-5900 m2/g) and large pore sizes (25-34 Å) 
making them particularly appealing for drug entrapment 44. For example, rigid mesoporous 
MIL-100 nanoMOFs, built up from trimers of iron(III) octahedra and trimesate anions, show 
two types of mesoporous interconnected cages accessible through microporous windows: i) 
large cages (~ 29 Å) delimited by hexagonal (~ 8.6 Å) and pentagonal (~ 4.8 × 5.8 Å) windows 
and ii) small cages (~ 25 Å) accessible exclusively by pentagonal windows 71. MIL-100(Fe) 
MOFs possessed the same architecture but with larger pore openings and adsorption surfaces. 
They were obtained by using aminoterepthalic acid instead of trimesic acid 45. 
 
Fig.8 Drug association to hybrid MOF nanoparticles. 
 
Drug loading by impregnation As shown in Table 1, a variety of active molecules have been 
successfully loaded into MIL nanoMOFs, including anti-inflammatory (ibuprofen, aspirin), 
antiviral (cidofovir, azidothimidine triphosphate (AZT-TP) and azidothimidine monophosphate 
(AZT-MP)), anticancer (busulfan, doxorubicin, ethoxysuccinato-cisplatin prodrug, 
gemcitabine-monophosphate (Gem-MP) and topotecan) drugs, nitric oxide, metallodrugs and 
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peptides. All these molecules were loaded by impregnation using preformed NPs. 
Advantageously, hydrophilic molecules such as azidothimidine mono-and triphosphate and 
gemcitabine monophosphate were entrapped simply by soaking from their aqueous solutions. 
The nanoMOFs acted as molecular sponges and the rapid and simple loading procedure lead to 
AZT-TP payloads of around 42 wt% and 21 wt% for MIL-101 and MIL-100 nanoMOFs, 
respectively72. Moreover, excellent loading efficiencies (> 95%) have been achieved, due to the 
high affinity of the phosphated molecules for the iron-based nanoMOFs 73,74. It has been shown 
by complementary techniques that coordination took place between the unsaturated Lewis acid 
iron sites and the phosphate groups of the drug 74. 
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Table 1. Drug encapsulation in MOFs by impregnation 
MOF Metal Ion Organic Linker Drug Drug Loading (%, w/w) 
CD-MOF (Cs) 75 Cs β-CD 5-FU 151 
CD-MOF (Cs) 75 Cs β-CD MTX 122 
CD-MOF (K) 31 K γ-CD fenbufen 20 
CD-MOF (K) 31 K γ-CD captopril 19 
CD-MOF (K) 31 K γ-CD flurbiprofen 12 
CD-MOF (K) 33 K γ-CD sucralose 28 
CD-MOF (K) 28 K γ-CD ibuprofen 26 
CD-MOF (Na) 76 Na α-CD 5-FU 9 
CD-MOF (Na) 76 Na α-CD MTX 38 
CD-MOF (Na) 76 Na α-CD silybummarianum 13 
CD-MOF (Na) 76 Na α-CD ferulic acid 11 
CD-MOF (Na) 76 Na α-CD quercetin 32 
Co-BBDA 77 Co H4BBDA 5-FU 15 
CNZTDH 78 Zn TATAT 5-FU 33 
CPO-27-Ni 79 Ni DHTPA NO 15 
Cu-BTC 80 Cu BTC 5-FU 45 
Gd-pDBI 81 Gd pDBI Doxorubicin 12 
HKUST-1 82 Cu BTC ibuprofen 34 
HKUST-1 82 Cu BTC anethole 38 
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HKUST-1 82 Cu BTC guaiacol 40 
HKUST-1 83 Cu BTC Nimesulide 17 
IFMC-1 84 Zn H3L 5-FU 30 
Mg2(OLZ) 
85 Mg Olsalazine Phenethylamine 11 
MIL-53(Fe)86 Fe terephthalic acid vancomycin 20 
MIL-53 (Cr) 87 Cr BDC ibuprofen 20 
MIL-53 (Fe) 87  Fe BDC ibuprofen 20 
MIL-53 (Al) 88 Al BDC peptides ‒ 
MIL-53 (Fe) 89 Fe BDC busulfan 10 
MIL-53 (Fe) 90 Fe BDC caffeine 29 
MIL-53-NH2 (Fe) 
91 Fe 2-amino terephthalic acid 5-FU 28 
MIL-88A (Fe) 89 Fe Fumaric acid busulfan 8 
MIL-88B (Fe) 92 Fe amino terephthalate caffeine ‒ 
MIL-89 (Fe) 89 Fe Muconic acid busulfan 14 
MIL-100 (Fe) 93 Fe BTC topotecan 33 
MIL-100 (Fe) 73 Fe BTC AZT-TP 36 
MIL-100 (Fe) 74 Fe BTC AZT-MP 24 
MIL-100 (Fe) 94 Fe BTC doxorubicin 31 
MIL-100 (Fe) 95 Fe BTC Gem-MP 30 
MIL-100(Fe) 96 Fe BTC aspirin 181 
MIL-100 (Cr) 97 Cr BTC ibuprofen 26 
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MIL-100 (Cr) 88 Cr BTC peptides ‒ 
MIL-100 (Fe) 89 Fe BTC busulfan 26 
MIL-101 (Cr) 88 Cr BDC peptides ‒ 
MIL-101 (Cr) 97 Cr BDC ibuprofen 138 
MIL-100 (Fe) 98 Fe BTC caffeine 50 
MIL-100(Fe) 99 Fe BTC RAPTA-C 42 
MIL-101 (Fe) 100 Fe BDC ethoxysuccinato-cisplatin 13 
MIL-101 (Cr) 101 Cr BDC naproxen ‒ 
MIL-101-NH2 (Fe) 
85 Fe amino terephthalate 5-FU 13 
MOF-74-Fe (II) 102 Fe DOBDC ibuprofen 16 
MOP-15 103 Cu 5-NH2-mBDC 5-FU 24 
NU-1000 104 Zr H4TBAPy calcein 37 
NU-901 104 Zr H4TBAPy calcein 42 
PCN-221 105 Zr H2TCPP MTX 40 
Rho-ZMOF 106 In H3ImDC Procainamide HCl 10 
Tb-mesoMOF 107 Tb H3TATB Vitamins B12 33 
UiO-NMOFs 108 Zr Amino-TPDC cisplatin 12 
UiO-NMOFs 108 Zr Amino-TPDC pooled siRNAs 82 
UiO-66 (Zr) 109  Zr BDC Caffeine 22 
UMCM-1 110 Zn BDC and H3BTB Ibuprofen 58 
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ZJU-800 111 Zr F-H2PDA Diclofenac sodium 59 
ZJU-101 112  Zr BPYDC Diclofenac sodium 55 
ZIF-8 113 Zn 2-methylimidazole Doxorubicin 20 
Zn-BDC 114 Zn BDC Ibuprofen 45 
Zn-CDDB 115 Zn CDDB 5-FU 54 
Zn-DDP 116 Zn H4DDP 5-FU 49 
Zn-TTA 117 Zn H4TTA 5-FU 21 
Abbreviation:  AZT-TP=Azidothymidine triphosphate; AZT-MP= Azidothymidine monophosphate; Gem-MP=Gemcitabin monophosphate 
BTC=1,3,5-Benzene tricarboxylic acid; RAPTA-C=[Ru(p-cymene)Cl2(pta)] ; BDC=1,4-Benzenedicarboxylic acid; DOBDC = 2,5-dioxido-1,4-
benzenedicarboxylate; OLZ=Olsalazine; amino-TPDC= Aminotriphenyldicarboxylic; UiO=Universitetet i Oslo; ZJU = Zhejiang University, ZIF= 
zeolitic imidazolate framework; F-H2PDA=(2E,2E′)-3,3′-(2-fluoro-1,4-phenylene)diacrylic acid; BPYDC=2,2′-bipyridine-5,5′-dicarboxylate; Zn-
CDDB=[Zn8(O)2(CDDB)6(DMF)4(H2O)]; CDDB = 4,4’-(9-H carbazole- 3,6-diyl)dibenzoic acid; Zn-BDC=[Zn(BDC)(H2O)2]n; 5-FU=5- 
fluorouraci; H3L =4,5-di(1H-tetrazol-5-yl)-2H-1,2,3-triazole); CNZTDH=[(CH3)2NH2]2 [Zn(TATAT)2/3]·3DMF·H2O; TATAT=5,5′,5′′-(1,3,5-
triazine-2,4,6-triyl)tris(azanediyl)triisophthalate; H3BTB=1,3,5-Tris(4-carboxyphenyl)benzene; 5-NH2-mBDC= 5-NH2-m-Benzenedicarboxylate; 
DHTPA=2,5-Dihydroxyterephthalic acid; pDBI=(1,4-bis(5-carboxy-1H-benzimidazole-2-yl)benzene); H3ImDC=4,5-imidazoledicarboxylic acid; 
H2TCPP= 5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin; MTX= Methotrexate; H4TTA = [1,1′:3′,1″-terphenyl]-3,3″,5,5″- tetracarboxylic acid; 
H4DDP= 2,6-di(3′,5′-dicarboxylphenyl)pyridine; H3TATB= triazine-1,3,5-tribenzoic acid; H4BIBDA= 5,5'-(biphenyl-4,4'- 
diyl-is(methylene))bis(oxy)diisophthalic acid; H4BBDA= 5,5'-(biphenyl-4,4'-diyl-is (methylene)) bis(oxy)diisophthalic acid; PCN= porous 
coordination network; HKUST= Hong Kong University of Science and Technology; MOP= Metal-organic polyhedral; UMCM= University of 
Michigan Crystalline Material.   
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In addition to MIL-family, a series of other MOFs were used as drug carriers, mainly Zn, Cu 
and Zr-based MOFs (Table 1). Several MOFs based on Ni, Gd, and In were also studied for 
drug encapsulation, with the advantages that some metal ions could confer also imaging 
properties. However, it has been pointed out that the toxicity of some metals could be a 
drawback for medical applications of some MOFs 118. 
Drug release was found to be strongly dependent on the nanoMOF stability in the release media. 
For instance, MIL-101 nanoMOFs with poor stabilities in aqueous media released AZT-TP in 
a fast (“burst”) manner, in contrast with the more stable MIL-100 nanoMOFs which keep their 
integrity over longer incubation times 72. As a general trend, it was found that the larger the 
pore size, the lower the MOF stability. Drug release from highly porous nanoMOFs appeared 
to be related to several factors: i) drug interaction with the metal sites and ligands; ii) drug 
diffusion inside the open porosity of the materials; iii) nanoMOF degradation kinetics in the 
release media. 
Moreover, it was found that in some case, drug incorporation inside nanoMOFs enabled 
stabilizing the matrix upon degradation. Topotecan (TPT), a hydrophilic cytotoxic drug was 
efficiently encapsulated in MIL-100 nanoMOFs filling the available space inside their large 
pores 93. The drug molecules formed aggregates inside the pores, which in turn strongly 
stabilized the crystalline tridimensional networks towards degradation in physiological media. 
Interestingly, TPT release could be triggered by two-photon light-irradiation, opening new 
standpoints for further developments in stimuli-induced drug delivery. Further studies are on 
the way to understand the release mechanism. 
Drug loading during particle synthesis A few recent examples show the possibility to load 
drugs in MOFs during their synthesis. Curcumin was successfully incorporated in CD-MOFs 
without altering their crystallinity. Interestingly, when dissolving the curcumin-loaded CD-
MOFs in water, unique complexes between curcumin, CD and potassium cations were found. 
The stability of curcumin in these complexes was enhanced by at least 3 orders of magnitude 
compared to curcumin: CD complexes. It was suggested that the CD-MOFs could be useful to 
store and stabilize curcumin for food applications 27.  
In another study, ferulic acid (FA) was strongly associated to CD-MOFs during their 
preparation by methanol vapor diffusion into an aqueous solution of γ-CD, KOH and FA. 
Differential scanning calorimetry studies indicated the formation of the stable association 
between FA and γ -CD in FA/CD-MOF 26. 
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BioMOF nanoMOFs were synthesized using the drug as a ligand to be directly linked to metal 
sites, thus building the tridimensional structures 119. These so called bioMOFs could load up to 
71.5 wt% of nicotinic acid. Disuccinatocisplatin was used as a linker to prepare NCP-1 120 (NCP 
stands for nanoscale coordination polymer). As most drug molecules possess metal complexing 
groups such as carboxylates, phosphates or amines, this approach bears a high potential for the 
development of biocompatible drug-delivery systems, maximizing the drug loading 
capabilities. Of note, bioMOFs containing therapeutically active molecules as a part of the 
structural framework are usually synthesized with a minimum number of synthetic steps for 
attaining maximum drug payloads.  
Some MOFs were composed of organic linkers which are not active molecules per se, but 
transform in physio-biological conditions to release active molecules. For instance, 1,3,5-
tris(1H-1,2,3-triazol-5-yl)benzene 121 and 2,5-dihydroxyterephthalic acid 122 were used as 
linkers releasing NO.  
Moreover, bioMOFs synthesized with active molecules as linkers could also be further used to 
encapsulate other drugs. Olsalazine-based porous MOF was successfully synthesized reaching 
51% (w/w) drug loading. Then, phenethylamine could be impregnated into the MOFs reaching 
a loading of 11% (w/w) 85 
Besides, the use of biologically active metal centers as a part of the MOF structure has lately 
been investigated. Thus, MOFs can act as reservoirs of metal ions, providing their gradual 
release to achieve a sustained antibacterial action. A variety of materials have been studied so 
far, including as metal ions Ag 123-125, Co 126, Cu 127 and Zn 128. 
2.3 Surface modification  
The application of nanoparticles for drug delivery is expected to make a difference in the field 
of biotechnology and pharmaceutical industries in the near future, as it paves the way to achieve 
targeted delivery in a cell- or tissue-specific manner, with the capability to bypass biological 
barriers (blood-brain barriers, epithelial and endothelial barriers, etc) and to visualize the in vivo 
fate of the nanocarriers by imaging modalities. Nanoparticle surface modification is a 
prerequisite to achieve these goals, as the interactions between the particles and the living media 
take place at their interface with the complex biological systems. However, the porous structure 
of nanoMOFs required the development of specific coating methods which do not alter the 
porosity and thus the loading capacity of the nanoMOFs. 
Silica coatings have been extensively used to modify the surface of both inorganic and polymer 
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nanoparticles 129-130. A variety of nanoMOFs have been coated with silica shells in an attempt 
to stabilize them, control their degradation, increase their biocompatibility and water 
dispersibility and enable further functionalization with a variety of silyl-derived molecules. 
Silica shells were synthesized on nanoMOFs made using a variety of metals, including Gd 131, 
Mn 132, Tb 133, Fe 100, and Zr 134. It was found that the silica shell significantly slowed down the 
nanoMOFs degradation. For example, the release of Gd3+ ions depended on the silica shell 
thickness. Silica-coated MIL-101 nanoparticles with the diameter of around 200 nm had a 
stability of around 14 h in PBS, while the uncoated ones readily decomposed 100. Moreover, the 
silica shell also allowed to control drug release depending on its thickness. Furthermore, the 
surface of these core−shell structures could be further modified by grafting silyl-derived 
molecules through surface silanol groups to impart additional functionalities, such as targeting 
ligands, optical contrast agents, and sensing agents. Interestingly, by grafting a cyclic arginine-
glycine-aspartate (targeting peptide), the anticancer efficacy against human colon cancer cells 
of Tb-based nanoMOFs was significantly increased as compared to the non-targeted MOFs 133.  
Reversible addition−fragmentation chain transfer (RAFT) polymerization was used to modify 
the surface of Gd-based NMOFs. Polymer-coating on nanoMOFs were achieved using a 
trithiocarbonate RAFT agent. The coatings were attached on the MOF surfaces through vacant 
coordination sites on the Gd3+ ions. The resulting polymer-coated Gd-MOFs were demonstrated 
to be biocompatible and had cancer cell targeting abilities and bimodal imaging properties 134-
136.  
Recently, simple, fast, and ‘‘green’’ strategies for functionalization of nanoMOFs were 
reported. MIL-100 (Fe) was ‘‘easily’’ coated by CD molecules bearing strong iron complexing 
groups (phosphates) 137 or by heparin 138.  The heparin coating endowed the nanoMOFs with 
improved biological properties, such as reduced cell recognition, lack of complement 
activation, and reactive oxygen species production 138.The stable CD-based coating was further 
functionalized with: i) targeting moieties to increase the nanoMOF interaction with specific 
receptors and ii) PEG chains to escape the immune system. These results pave the way towards 
the design of surface-engineered nanoMOFs of interest for applications in the field of targeted 
drug delivery. Polysaccharides like dextran and chitosan were studied to improve the solubility, 
cellular adhesion and imaging properties of native MOFs 139. 
Lipid coatings have recently been used to modify the surfaces of MIL-100 (Fe)140. Dye 
molecules were entrapped in the resulting MOF@lipid systems. It was shown that the lipid 
bilayer could: I) prevent the premature release of the dye, II) increase the colloidal stability of 
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the nanoparticles and III) favored a higher uptake by cancer cells as compared to uncoated 
particles. Amorphous MOFs or nanoscale coordination polymers, were also coated with lipid 
coatings 141-144. The pH-responsive coatings have also been developed. 
Doxorubicin loaded MIL-101 was functionalized with pH responsive benzoic imine bond and 
a redox active disulfide system. Both in vitro and in vivo results demonstrated that this system 
efficiently inhibited cancer cell growth while showing reduced side effects 145. Chitosan-
modified magnetic nanoMOFs loaded with doxorubicin showed pH-responsive drug release for 
several days. Moreover, the particles could be modified with folic acid, a target molecule, which 
allowed a more specific cellular internalization in folate-overexpressing cancer cells (HeLa) in 
comparison to normal (L929) cells 146. 
2.4 In vivo studies  
For biomedical and pharmaceutical applications, MOFs are firstly required to have 
toxicologically compatible features. Nine representative nanoMOFs were assessed to zebrafish 
embryos, including barely cytotoxic (nanoUiO-66, nanoUiO-67, and nanoCo-MOF-74, and 
nanoMg-MOF-74), moderately cytotoxic (nanoZIF-7, nanoMIL-100, and nanoMIL-101), and 
highly cytotoxic (nanoZIF-8 and nanoHKUST-1). It is found that at 120 h post fertilization, the 
viabilities of the embryos exposed to nanoCo-MOF-74, nanoMg-MOF-74, nanoUiO-66, 
nanoUiO-67, nanoMIL-100, and nanoMIL-101 were not significantly different to those of the 
control group (without nanoMOFs), even at highest concentration (200 µM). In contrast, 
nanoZIF-7, nanoZIF-8, and nanoHKUST-1 provoked significant decreases in embryo survival. 
NanoZIF-7 was slightly toxic at 200 µM (embryo viability 79.2%); nanoZIF-8 was more toxic 
at the same concentration (embryo viability 33.3%); and nanoHKUST-1 was extremely toxic 
even at 20 µM (viability: 0%). It was shown that the leaching of solubilized metal ions played 
a main role on the levels of the MOF toxicity147.  
Toxicity of iron trimesic MIL-100 (Fe) and trimesic acid were performed through intravenous 
administrating to rats. Around 220 mg/kg of MIL-100 and 78 mg/kg trimesic acid were 
intravenously injected and the results showed that the animal behavior and weight evolution of 
injected rats were totally normal in comparison with control group. It was concluded that this 
material is acceptable for drug delivery 148. Biodistribution of MIL-100 nanoMOFs at early 
times (up to 24 h) or long term (from 24 h to 1 month) after administration were evaluated. The 
pharmacokinetic profile suggested that the nanoparticles act as a depot in the blood stream 
during the first hours before being cleared. Accumulation took mainly place in the liver and, in 
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some extent, in the spleen. Histological studies demonstrated the absence of morphological 
alterations due to the presence of the particles in these organs. Liver function was however 
slightly altered as reflected by the increased plasma aspartate aminotransferase concentrations. 
Finally trimesate was progressively eliminated in urine. Nevertheless, it was demonstrated that 
in the long-term study, these abnormalities in the iron levels were completely reversed after 
seven days and were not related to any toxicity signs. 
Despite the paramount importance of in vivo experiments, there are only scarce examples 
showing in vivo data, certainly because of nanoMOFs’ novelty in the biomedicine domain. 
Simon-Yarza et al. reported the first in vivo results with MIL-100 nanoMOFs loaded with the 
antineoplastic drug busulfan. Drug-loaded nanoMOFs were administered to rats and compared 
with the commercial Busilvex®. Large differences in serum concentration of both busulfan and 
the constitutive ligand (trimesate) revealed the great impact of drug encapsulation both on the 
drug and on nanoparticle pharmacokinetics during the first 24 h of administration149.  
Tumor targeting MOFs (TTMOFs) based on MIL-101 were successfully developed via surface 
modification with polymers comporting pH responsive benzoic imine bonds and redox 
responsive disulfide bonds.  In vivo experiments showed that doxorubicin-loaded TTMOFs 
could effectively inhibit tumor growth with minimal side effects 145.     
2.5 Imaging with MOF  
Magnetic resonance imaging (MRI). MRI is a powerful and noninvasive diagnostic imaging 
technique allowing the detection of nuclear spin reorientations with high spatial resolution. 
Contrast agents are used to improve the image quality by reducing the proton relaxation times. 
NanoMOFs have received attention as contrast agents because of their hybrid composition 
consisting of metal centers and organic ligands. Moreover, as all other types of nanoparticles, 
they can be engineered in order to accumulate in targeted organs or tissues of interest (such as 
tumors) either by “passive targeting” via enhanced permeability and retention effect, or by 
“active targeting” using various target-ligands 150. Firstly, Gd3+ -containing nanoMOFs have 
shown high relaxivities as T1-weighted contrast agents. They possessed increased relaxivities 
as compared to the clinically used Omniscan. Gd-based nanoMOFs endowed with multimodal 
imaging properties were further developed. For instance, both a specific ligand and a 
fluorophore were grafted onto the nanoMOF surfaces enabling to achieve a tumor-targeted MRI 
effect 132.Multifunctional MOFs endowed with bimodal imaging properties via MRI and 
fluorescence microscopy were synthesized for tumor targeting and diagnostic imaging 136.A 
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variety of MOFs endowed with imaging properties was synthesized, including as metal ions Cu 
151, Ru 134 Eu 131, and Tb 152. Although the relaxivities of Mn2+-based nanoMOFs were modest, 
the possibility for site-specific imaging with the help of a silica shell at the surface of 
nanoMOFs has been demonstrated132 . Fe3+-containing nanoMOFs possessed good T2-weighted 
contrast enhancement. 72.  MRI measurements on Wistar female rats shows that the treated liver 
and spleen organs were darker than the normal ones, because of the preferential accumulation 
of the nanoMOFs in these organs. However, three months after injection, the liver and spleen 
returned to a similar appearance to that of the untreated rats, in accordance with the temporary 
accumulation of the nanoMOFs in these organs. Recently, a multifunctional nanoplatform 
based on isoreticular metal organic frameworks (IRMOF-3) was developed. Folic acid and the 
fluorescent molecule rhodamine B isothiocyanate (RITC) were both conjugated to the 
nanoMOF surface for cancer cell targeting and optical imaging. Paclitaxel was loaded into these 
magnetic nanoMOFs. The targeted nanoMOFs showed stronger T2-weighted MRI contrast 
towards cancer cells 153. 
X-ray Computed Tomography (CT) Imaging. CT imaging is based on specimen attenuation of 
X-rays and can provide 3D images with excellent spatial resolution. Typical contrast agents are 
materials containing high Z number elements, including iodine, barium and bismuth. Currently, 
barium sulfate and iodinated aromatic are used clinically for intravenous and gastrointestinal 
tract imaging, respectively. The contrast agents for CT have the same drawbacks as for MRI, 
including a non-specific distribution and a fast clearance. Therefore, nanoMOFs have been 
developed as carriers for iodinated aromatic molecules 154. They were prepared using tetra iodo 
benzene dicarboxylic acids as bridging ligands and Cu2+ or Zn2+ as metal connecting points. 
The efficacy of the resulting iodinated nanoMOFs for CT has been clearly demonstrated.  
All the above presented studies highlight the potential of nanoscale MOFs as platforms for MRI 
and X-ray CT. 
Conclusion 
Despite an enormous amount of research in the area of nanomedicine and advanced nano-
carriers drug targeting in cancer, the transition from laboratory to the market is usually very 
slow and unpredictable. The majority of the problems arise from effective oversight in safety- 
and efficacy-by-design approach for nanomedicines. “Cage” particles based on “CD” and 
MOFs were shown to be biocompatible and versatile materials, adapted for drug incorporation. 
Moreover, their “green” scalable preparation positions these materials as good candidates for 
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biomedical application. They are promising carriers for various drugs, including antibiotics, 
anticancer and anti-inflammatory drugs, etc. 
CDs are recognized as “molecule containers” to form inclusion complexes with a variety of 
active molecules. These inclusion could not only improve the solubility and bioavailability of 
poorly soluble drugs, stabilize drugs from light, thermal and oxidative degradation, mask the 
bitter taste of the drugs, but also can be used as the driving forces to form NPs. Remarkably, 
the NPs spontaneously formed by CD inclusion complexes are easily formed by “green” 
methods, in absence of organic solvents or surfactants. While self-assembled NPs composed of 
CDs are attractive formulations, the stability of the formed NPs need to be studied in depth 
upon dilution, since the supramolecular edifices are constructed solely on the basis of non-
covalent bonds. Indeed, in theory, the inclusion complexes are prone to dis-assemble upon 
extreme dilution, leading to the destructuring of the NPs.      
CD-MOFs are a new type of porous CD-based particles, which contain not only the cavities of 
CDs, but also the big pores built up by CDs self-assemblies (Fig.1). Compared with CD based 
NPs, CD-MOFs have the possibility to load drugs with higher payloads. Given the fact that the 
particles disassemble in water, we foresee that a promising administration route could be 
pulmonary inhalation. However, with appropriate surface modification, the stability of CD-
MOFs was significantly improved, which broadens their application also for potential oral and 
intravenous administration. 
MOFs, especially biodegradable MOFs stable in aqueous media, have drawn a lot of attention 
as drug delivery systems. MIL-100(Fe) was considered among the most efficient material as 
drug carrier due to its large pore size, biocompatibility and biodegradability. A variety of drugs 
have been efficiently encapsulated, including anti-inflammatory (ibuprofen, aspirin), antiviral 
(cidofovir, AZT-TP and AZT-MP), anticancer (busulfan, doxorubicin, ethoxysuccinato-
cisplatin prodrug, Gem-MP and topotecan) drugs. There are two types of cages in the structure 
of MIL-100(Fe), so it could be possible to load two drugs simultaneously in the same particles 
in theory. To the best of our knowledge, studies so far report only the incorporation of one drug 
in the same particles. In this context, it would be interesting try to entrap synergic drugs in the 
same particles to treat complex pathologies such as cancer and severe viral or bacterial 
infections.          
By taking advantage of their specific characters such as green preparation procedure, high drug 
payloads, and co-encapsulation of synergic drugs, these “cage” particles, these “cage” particles 
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are very promising for drug delivery applications.  
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Chapter 2 
Spontaneous self-assembly of polymeric nanoparticles in aqueous media: 
new insights from microfluidics, in situ size measurements, and individual 
particle tracking 
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General Objectives and Author Contributions 
CD-based nanotechnology has drawn special attention since it combines the advantage of self-
assembled host-guest interactions and nanotechnology. Herein, polymeric nanoparticles driven 
by CD inclusion complexes were spontaneously formed in aqueous media, in the absence of 
organic solvents or surfactants. In order to prepare stable CD-based nanoparticles (CD-NPs), a 
highly soluble β-CD polymer (poly-CD) was used as the source of CDs, which was prepared 
by cross-linking β-CD with epichlorohydrin (EP). Benzophenone (Bz) was chosen as the guest 
molecule, because of its strong affinity with the cavity of β-CD and because it was well-studied 
in NPs made of poly-CD. Bz was grafted with dextran, forming a new polymer, namely, Dex-
Bz. Poly-CD and Dex-Bz were used in this study as the two polymers for CD-NPs preparation. 
They are both neutral polymers, therefore, the interactions between the two polymers in water 
are mostly due to the host-guest interactions between β-CD and Bz, without electrostatic 
interactions. 
    To prepare and characterize these particles, complementary methods were used bringing new 
insights on the formation and stability of the supramolecular systems:  
    1) Microfluidics was used to prepare the particles by mixing the two aqueous solutions 
directly in the microfluidic chamber. CD-NPs with narrow size distributions were immediately 
formed upon contact of the two polymeric solutions. 
    2) In situ size measurements during the particle formation showed that the CD-NPs were 
spontaneously formed in aqueous media.  
    3) Individual particle tracking analysis was used to gain insights on their size distribution and 
concentration. Since the CD-NPs were formed by non-covalent interaction, it is important to 
check if the NPs disassemble upon dilution. Individual particle tracking analysis was an adapted 
method to prove that the particles were stable even upon extreme dilution despite their non-
covalent nature. 
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Chapter 3 
Particles based on CD-MOFs and their biomedical applications 
 
 
Subchapter 3.1 
Optimized synthesis and crystalline stability of γ-cyclodextrin  
metal-organic frameworks for drug adsorption 
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General Objectives and Author Contributions 
As previously described, CD-MOFs have gained increased popularity as drug carrier since it is 
environment-friendly biocompatible and even “edible” MOFs. It is widely recognized that size 
distribution and stability are crucial parameters for drug delivery system.   
In the originally reported protocols for their synthesis, the size of CD-MOF crystals was around 
200-400 µm. It was then discovered that addition of cetyltrimethyl ammonium bromide 
(CTAB) in the preparation enabled the formation of smaller crystals (1-10 µm). However, the 
synthesized crystals had a large polydispersity. Moreover, the syntheses were carried out at 
room temperature over long time periods of time (> 24 h).  
Herein, we optimized the synthesis procedure by heating at 50 °C within 6 h with pre-addition 
of the reaction solvent to obtain uniform cubic γ-CD-MOF crystals. The factors that affect the 
size of CD-MOFs were systematically investigated, including the reactant concentrations, 
temperatures, time, γ-CD ratios to KOH and surfactant concentrations. Subsequently, the 
stability of CD-MOFs were studied under conditions of high temperature (100 °C), high 
humidity (92.5%) and polar solvents (e.g., MeOH and DMF). Finally, drug absorption of CD-
MOF was evaluated with different kinds of drugs. It is discovered that most of the drug 
molecules containing carboxyl groups showed relatively high adsorption (> 5%), while low 
adsorption (< 5%) was found for drugs with nitrogen-containing heterocyclic rings. This study 
pave the way towards the use of CD-MOFs for drug delivery purposes. 
This study has been performed in collaboration with Dr. J. Zhang in Shanghai Institute of 
Materia Medica in China. X. Li contributed to perform the experiments on CD-MOFs synthesis.  
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Subchapter 3.2 
Cyclodextrin-based metal-organic frameworks particles as efficient carriers for 
lansoprazole: study of morphology and chemical composition of individual particles 
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General Objectives and Author Contributions 
In this subchapter, CD-MOFs around 6 µm with monodispersed size distribution were used as 
drug carrier for Lansoprazole (LPZ). The molecular dimensions of LPZ is about 4 × 17 Å, 
which fits to the dimensions of γ-CD cavity (7.8 Å) and the internal spherical cavities (17 Å) 
of CD-MOF.   
In addition to drug absorption by impregnation shown in subchapter 3.1, a new approach was 
used in this subchapter for drug encapsulation, namely, co-crystallization. By impregnation 
approach, the obtained payloads were not as high as expected, at best around 12.6% (wt) in the 
case of captopril, possibly because the small pore windows of the CD-MOFs limit the 
penetration of drugs. Therefore, co-crystallization was used for LPZ, where the drug was added 
during particle synthesis. Remarkably, LPZ payloads reached 23.2±2.1% (wt) which 
corresponds to a molar ratio of 1:1 between LPZ and γ-CD. 
To well characterize the LPZ loaded CD-MOFs, the study of morphology and chemical 
composition of individual particles was performed with Raman microscopy. It was 
demonstrated that there were no significant differences on Raman spectra of individual 
particles, indicating that each individual particle had identical chemical composition. Molecular 
modelling was performed for deeper insight into the interaction between the LPZ and CD-
MOFs. Moreover, it was demonstrated that even after two years storage, the incorporated drug 
inside the CD-MOFs maintained its spectroscopic characteristics. This study lay the 
foundations for further application of CD-MOFs as LPZ carriers for drug delivery. 
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Subchapter 3.3 
Composite CD-MOF nanocrystals-containing microspheres for sustained drug delivery 
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General Objectives and Author Contributions 
CD-MOFs have shown their high drug loading capacity up to 23% (wt) in subchapter 3.2, 
however, their applications in the biomedical field are severely hampered by their physical 
frailness and their high solubility in aqueous media. Therefore, surface modification is needed 
in order to improve the stability of CD-MOFs in aqueous media and also to control the drug 
release. Herein, CD-MOFs were embedded in a biocompatible polyacrylic acid (PAA) polymer 
matrices by a solid in oil-in-oil (s/o/o) emulsifying solvent evaporation method. Briefly, several 
steps were included: 
1) Nano-scaled CD-MOFs were firstly synthesized to obtain a good dispersion inside PAA 
matrices. 
2) Drugs of interest, Ibuprofen (IBU) and Lansoprazole (LPZ), were loaded in CD-MOFs by 
co-crystallisation.  
3) Morphology, size distribution, and crystallinity of CD-MOFs, loaded or not with drugs were 
well characterized. 
4) CD-MOF nanocrystals-containing microspheres, namely drug-CD-MOF/PAA composite 
microspheres, were prepared by a solid in oil-in-oil emulsifying solvent evaporation method. 
As controls, microspheres containing only drug, or drug-CD complex were prepared in parallel. 
5) Morphology, size, and drug release of the prepared microspheres were investigated.  
6) The cellular toxicities of CD-MOF nanocrystals, blank PAA microspheres, pure IBU, IBU-
CD-MOF nanocrystals and the IBU-CD-MOF/PAA composite microspheres were evaluated in 
J774 macrophages using MTT assay. 
As a result, the composite microspheres exhibit not only spherical shapes and sustained drug 
release over a prolonged period of time, but they also demonstrate reduced cell toxicity.  
This work has been performed in collaboration with Dr. J. Zhang in Shanghai Institute of 
Materia Medica (China) and Dr. J. F. Stoddart in Northwestern University (USA). X. Li 
conducted the experiments with LPZ. N. Lv focused on IBU related experiments, and Dr. H. Li 
contributed to data analysis and manuscript writing.  
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Chapter 4 
Particles based on Iron-trimesate MOFs and their biomedical applications 
 
 
Subchapter 4.1 
New insights into the degradation mechanism of metal-organic frameworks 
drug carriers 
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General Objectives and Author Contributions 
"Cage" porous particles based on MOFs have emerged as a new class of ordered porous 
materials for drug delivery. Iron trimesate MOFs: MIL-100 (Fe) are considered among the most 
efficient materials because of their biodegradability, biocompatibility, and unprecedented drug 
loading capability. Among all the investigated molecules, MIL-100 (Fe) interacted most 
efficiently with phosphated ones which could be efficiently soaked from their aqueous 
solutions. However, MIL-100 (Fe) rapidly degraded in phosphate buffers. It is important to 
understand the complex interactions taking place between MIL-100 (Fe) and different phosphated 
molecules. Therefore, in this subchapter, we developed a method based on Raman microscopy 
to track the morphology and chemical composition of individual particles. 
Briefly, the degradation of nanoMOFs and microMOFs were firstly studied in phosphate buffer 
saline (PBS). In particular, the degradation behavior of individual particles in PBS was tracked 
by Raman microscopy. Of upmost interest, it was possible to detect modifications of the 
chemical composition on different regions on the same particle during degradation. A formation 
of an erosion front during MOF degradation was clearly observed with obvious modification 
on Raman spectra.  
To understand if the phosphated molecules would lead to degradation, Gemcitabine-
monophosphate (Gem-MP) and β-CD-phosphates (CD-P) were chosen as model molecules. 
Gem-MP is a small molecule could be penetrated within the porous MOF structures, in contrast, 
CD-P is larger than the cage of MOF and could stay only on the surface of the particles as 
coating material. In both cases, phosphated drugs/coating materials did not contribute to particle 
degradation. 
All the authors have contributed in this work. X. Li contributed to experiments on the 
nanoMOFs synthesis, characterization, surface coating, and drug loading, and wrote the main 
manuscript.  
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Abstract  
A versatile method based on Raman microscopy was developed to follow the degradation of 
iron carboxylate Metal Organic Framework (MOF) nano- or micro-particles in simulated body 
fluid (phosphate buffer). The analysis of both the morphology and chemical composition of 
individual particles, including observation at different regions on the same particle, evidenced 
the formation of a sharp erosion front during particle degradation. Interestingly, this front 
separated an intact non eroded crystalline core from an amorphous shell made of an inorganic 
network. According to Mössbauer spectrometry investigations, the shell consists essentially of 
iron phosphates. Noteworthy, neither drug loading nor surface modification affected the 
integrity of the tridimensional MOF network. These findings could be of interest in the further 
development of next generations of MOF drug carriers. 
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Introduction  
Metal-organic frameworks (MOFs) are a recent class of ordered porous materials formed by 
the coordination of metal clusters and organic ligands. Due to their versatile chemistry, high 
pore volumes and large surface areas, MOFs attracted growing interest in various areas, 
including gas storage1,2, catalysis3-5, separation science6, sensing7,8, ionic conduction9 and 
more recently, biomedicine10-13. Lately, biodegradable micro- or meso-porous iron 
polycarboxylate MOFs were employed as drug carriers10,11,14-18. More particularly, iron 
trimesate MIL-100 and iron terephthalate MIL-101 (MIL stands for Materials of Institute 
Lavoisier) were considered among the most efficient materials to load drugs because of their 
large pore sizes (24-29 and 27-34 Å for MIL-100 and MIL-101, respectively)19.  As an example, 
ibuprofen payloads reached up to 35 wt% and 140 wt% for MIL-100 and MIL-101, 
respectively11. However, nano-scaled MOFs (nanoMOFs) made of biocompatible MIL-101(Fe) 
suffer from a very fast degradation in phosphate buffer saline (PBS) hampering their 
applications for controlled drug delivery20. In contrast, MIL-100(Fe) nanoMOFs degraded in a 
more progressive manner compatible with biomedical applications and were well tolerated in 
vivo21. A variety of drugs have been successfully incorporated into MIL-100(Fe) nanoMOFs, 
including antiviral drugs (cidofovir10, azidothimidine triphosphate (AZT-TP) and 
azidothimidine monophosphate (AZT-MP))15,22, anticancer drugs (busulfan16, topotecan18, 
doxorubicin23 and gemcitabine-monophosphate (Gem-MP)24), biological gases (nitric oxide)25, 
caffeine26, aspirin27 and metallodrugs28. 
The highest loading efficiencies were reported in the case of phosphated drugs, including AZT-
TP, AZT-MP and Gem-MP15,22,24. MIL-100 were able to soak the drugs within minutes from 
their aqueous solution, reaching elevated drug loadings (around 30, 25 and 36 wt% for Gem-
MP, AZT-TP and AZT-MP, respectively) and encapsulation efficiencies higher than 98%. It 
was demonstrated that coordination of the drug’s phosphate groups on the iron(III) Lewis acid 
sites in MIL-100 nanoMOFs played a main role, leading to an efficient encapsulation22,24. 
Indeed, the same drugs without phosphate groups were poorly incorporated22. 
Phosphate molecules are essential components in every living organism. When non-controlled, 
strong interactions between phosphates and MOFs can lead to a fast degradation and thus to 
“burst” drug release. Therefore, it is of outmost importance in the development of MOFs drug 
carriers to gain deep understanding on their degradation in the presence of phosphates. It was 
shown that MIL-100(Fe) particles exhibit good colloidal stability and biodegradability in a 
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series of simulated physiological fluids29 and the degradation of nanoMOF has been studied in 
different cell culture medium as reported29. There was around 10wt% of trimesate released in 
Dulbecco's Modified Eagle's medium (DMEM), but only around 5% released in Minimum 
Essential Medium Eagle (MEM). Trimesate release was dependent on the composition of the 
cell culture medium, especially on its content in phosphates. Intravenously administered 
nanoMOFs in rats were rapidly sequestered by the liver and spleen, then further biodegraded 
and directly eliminated in urine or feces30. The trimesate linkers were progressively eliminated 
in urine21. All these studies have shown the biodegradability of nanoMOFs for potential 
biomedical applications, but their degradation mechanism is not fully understood yet. . 
Recently, Bezverkhyy et al.32 demonstrated that MIL-100(Fe) nanoMOFs maintained their 
crystalline structures while heated in water at 100 °C for 48 h, but partially degraded. On the 
contrary, at neutral pH the particles degraded within one hour yielding poorly crystallized iron 
oxide (ferrihydrite). These experiments were however conducted in media without phosphate 
groups, not mimicking the biological conditions. In other studies, it was shown that the MIL-
100(Fe) nanoMOFs progressively disintegrated in PBS because of the strong interactions 
between phosphates and iron and that this degradation was well correlated to drug release15,18,23.  
One can also tailor the MOF particle size according to the targeted application and route of 
administration even leading to micron-sized MOF (microMOF) particles33. NanoMOFs had 
been reported to exhibit a narrower particle size distributions than microMOFs but were more 
prone to faster degradation because of larger surface areas33.  However, no study dealt yet with 
the influence of the MOF particle size on the degradation mechanism. Moreover, the 
investigations on MIL-100(Fe) MOF degradation were conducted so far using batches of 
particles, but never on individual particles. In addition it has not been assessed yet at the particle 
level if drug loading or surface modification impacts the stability of the nanoMOF. It is 
therefore of main interest to study the degradation of individual MOFs. 
To address this goal we have used here Raman microscopy to monitor in situ the degradation 
in phosphate-containing media of individual MIL-100(Fe) MOF particles of different sizes. 
This versatile method combines the advantages of both Raman spectroscopy and optical 
microscopy. The utility of Raman microscopy as a rapid, label-free, and non-destructive method 
was proven in many applications where chemical analysis and imaging are simultaneously 
required. This technique allows to qualitatively or quantitatively characterize the chemical 
composition and structure of a sample. In the pharmaceutical field, Raman microscopy is used 
mainly to characterize the distribution of molecules of interest in tablets, to determine the 
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crystallinity of the materials, to investigate purity and chemical composition of complex 
devices.  
In this study, MOF batches were analyzed in terms of particle size distribution and shape. 
Raman spectra of individual particles were recorded, enabling to assess the homogeneity of the 
MOF population in terms of chemical composition and morphology. Of note, the degradation 
of each particle in PBS was monitored up to 8 days, enabling to detect eroded and intact zones 
in the same particle. Finally, we showed that the integrity of the MIL-100(Fe) MOFs was 
maintained after drug loading and surface modification. 
Results and discussion 
Synthesis and characterization of nanoMOFs. Nano-scaled MIL-100(Fe) particles were 
successfully prepared as reported by a solvent-free and fluoride-free “green” hydrothermal 
microwave assisted method using as reactants iron chloride and trimesic acid34. As schematized 
in Fig.1A, the spontaneous coordination of Fe(III) trimers and trimesic acid generates hybrid 
supertetrahedra which further assemble into a zeotypic architecture consisting of: i) small 
mesoporous cages (Ø =25 Å), delimited by pentagonal openings (5.6 Å) and ii) large 
mesoporous cages (Ø =29 Å) accessible through both pentagonal and larger hexagonal 
windows (8.6 Å)11. The nanoMOFs’ Powder X-Ray Diffraction (PXRD) patterns and nitrogen 
porosimetry BET surface areas (SBET = 1690 ± 50 m
2/g) are in agreement with previously 
published data15,19.  
As illustrated in Fig.1B, the nanoMOFs appear as small crystals with a faceted morphology and 
rhombic structures. The Transmission Electron Microscopy (TEM) analysis of more than 8000 
nanoMOFs particles allowed estimating their average diameter of 187 ± 55 nm and a mean 
circularity of around 0.89 (Fig, 1C) in agreement with the sharp-edged shapes observed by TEM 
(Fig 1B). The mean diameter of the nanoMOFs measured by Differential Light Scattering 
(DLS, number values) is 216 ± 21 nm with a polydispersity index (PdI) of 0.131. 
In a complementary approach, the size of individual nanoMOFs was determined by 
nanoparticle tracking analysis (NTA), a method which combines an optical microscope and a 
laser illumination unit35. The mean diameter of each particle was calculated from its trajectory 
in Brownian motion, using the Stokes–Einstein equation. The obtained mean diameter of 196 ± 
59 nm (Fig.1D) was in agreement with those obtained by both DLS and TEM studies. These 
findings support the fact that the nanoMOFs have a relatively narrow particle size distribution. 
Synthesis and characterization of MIL-100(Fe) microMOFs  
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MicroMOFs were synthesized by a similar method as nanoMOFs, but with longer reaction 
times to allow the crystals to grow larger. The microMOFs displayed a crystalline structure 
according to PXRD patterns and nitrogen porosimetry BET surfaces of around 1700 ± 60 m2/g. 
More than 2000 individual particles were observed by Raman microscopy. Typically, the 
microMOFs appeared as crystals with irregular shapes (Fig. 1E). Statistical analysis showed 
that microMOFs possess a mean circularity (0.84) slightly lower than the nanoMOFs (Fig. 1F). 
MicroMOF samples contained: i) a main population with an average diameter of around 3 µm 
and ii) a smaller population of much larger particles of size around 60 µm (Fig. 1G). Contrary 
to nanoMOFs which had a narrow size distribution, microMOFs possess thus a bimodal size 
distribution, possibly because of the difficulty to control crystal nucleation and growth, a 
process dependent on many experimental parameters. These findings highlight the importance 
to perform individual particle analysis to gain insights into the degradation of MIL-100(Fe) 
particles of different sizes. 
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Fig.1. Schematic representation of the “green” hydrothermal synthesis of MOFs (A) and their 
morphological characterization, including TEM images of nanoMOFs (B) and optical images 
of microMOFs (E); circularity for nanoMOFs (C) and microMOFs (F) calculated from more 
than 8000 particles for nanoMOFs and 2000 particles for microMOFs, respectively, as well as 
size distributions for nanoMOFs (D) and microMOFs (G). Iron polyhedra, oxygen, carbon 
atoms are in orange, red and black, respectively. 
Degradation of nanoMOFs 
To study the effect of phosphates on nanoMOF degradation, the crystalline particles were 
incubated in PBS with different phosphate concentrations and in water, as a control. NanoMOFs 
incubated in PBS (1.19 mM) at 37°C experienced a rapid degradation, releasing large amounts 
(34 ± 3 wt %) of their constituting ligand, trimesate, after only 6 h. These data are in agreement 
with previously reported studies, where 29.9 ± 2.1 wt% trimesate was released under similar 
conditions 28. Comparable amounts of ligands (31 ± 3 wt %) were released but after two days 
of incubation in PBS when diluted ten times (0.12 mM)(for details see SI section). In both cases, 
the concentration of nanoMOFs was 0.5 mg/mL, corresponding to 0.1 mM Fe. This highlights 
the influence of the concentration of phosphates on the degradation mechanism: the higher the 
concentration of phosphates, the faster the degradation of nanoMOFs in PBS.  
In contrast, nanoMOFs released negligible amounts (less than 2 wt %) of their trimesate 
constituting ligand within two days incubation in pure water at 37°C, in agreement with 
previous investigations 15,22, where less than 1 wt% trimesate was released after incubation for 
three days. This is in agreement with the nanoMOFs’ diameter that remained practically 
unchanged over two days incubation in water (224 ± 25 nm).  
Note that nanoMOFs lost their crystallinity in PBS within only 4 h, whereas they maintained 
an intact crystallinity in water, as indicated by PXRD results (Fig. S1). 
These observations were well corroborated by TEM investigations, evidencing the nanoMOF 
morphological aspects before (Fig. 2A) and after (Fig. 2B) degradation in PBS. Noteworthy, 
degradation in PBS leads to a progressive rounding (Fig. 2B) of the nanoMOF sharp initial 
edges (Fig. 2A), in agreement with a progressive disorganization of the crystalline 3D structure. 
Interestingly, DLS measurements showed that despite the degradation, the nanoMOFs 
maintained practically the same mean diameter (Fig. 2C), with a moderate decrease in size from 
221 ± 24 nm to 187 ± 22 nm after two days incubation in PBS, despite the fact more than 30 % 
of their constitutive ligand has left the particles, as shown above.   
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In a nutshell, it confirms that these iron carboxylate based nanoMOFs are remarkably stable in 
water, but degrade in PBS with a progressive departure of the constitutive organic linkers 
associated with an amorphization. However, it is remarkable that despite their dramatic 
morphological and structural changes in PBS, nanoMOFs maintain practically unchanged 
diameters over two days. Based on these findings, it was interesting to further investigate the 
degradation of larger particles (microMOFs) in PBS. 
Degradation of MIL-100(Fe) microMOFs 
As shown in Fig.2D, MIL-100(Fe) microMOFs are red-orange crystals with irregular shapes. 
The red color is attributed to Fe3+ species in the [Fe3O(OH)(H2O)2]
6+ clusters linked by 
carboxylate anions27. Contrary to nanoMOFs, microMOFs degrade very slowly and therefore 
concentrated PBS (11.9 mM) was used to accelerate the process. After 8 days of incubation in 
this medium, the particles changed color (Fig. 2E). However, surprisingly, the size of the 
particles monitored by Raman microscopy remained unchanged (less than 0.5 % variation in 
all dimensions) (Fig. 2F) as it was previously shown in the case of nanoMOFs. Grey regions 
(arrows in Fig. 2E) were clearly observed, whereas the core of the particles maintained its initial 
red color.  
In a nutshell, MOF particles degraded with the formation of a grey shell delimiting a red-colored 
core. Raman microscopy was further used to study the composition of these different regions 
in the same particle. 
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Fig.2 Morphology of MIL-100(Fe) nano-and microMOFs and size variations after incubation 
in water or PBS.  TEM images of nanoMOFs before (A) and after (B) degradation in PBS (1.19 
mM) for 6 hours. Size variation (C) of nanoMOFs (100 µg/mL) in MilliQ water (orange) and 
PBS (0.12 mM, blue) for 2 days. Images of microMOFs observed by Raman-microscopy before 
(D) and after (E) degradation in PBS (11.9 mM) for 8 days; size distribution (F) of microMOFs 
before (green) and after (red) degradation.  
Individual MIL-100(Fe) particle degradation  
Typical Raman spectra of microMOFs show the specific MIL-100(Fe) peaks in the 100-1900 
cm-1 region (Fig. 3). The peak A at 210 cm-1 is attributed to the ordered crystalline iron-based 
structure, whereas the B bands from 450 cm-1 to 600 cm-1 are related to lattice vibrations and 
network binding modes. The principal peaks in Fig. 3 correspond to the fingerprints of the 
trimesate linker, the aromatic ring peaks at 800 cm-1 (peak C) and 1000 cm-1 (peak D). The E 
peaks around 1200 cm-1 can be assigned to the C–O–Fe stretching of Fe-trimesate, whereas F 
bands ranging from 1400 cm-1 to 1600 cm-1 are related to the H–O–H bonding vibrations, which 
indicate that the Fe-trimesate network contains coordinated water. 
Figure 3 presents a typical image of a microMOF particle before (left) and after 8 days 
degradation in PBS (right). The morphology was dramatically changed with the appearance of 
a sharp transition delimiting a red-colored core (region I) from a grey shell (region II). Of note, 
Raman microscopy enabled monitoring Raman spectra in both I and II regions. The spectrum 
of region I consisted of peaks very similar to those characteristic of non-degraded MOFs, with 
the exception of peak D which was broadened at its base. On the contrary, in region II, all peaks 
disappeared and only a large peak D could be detected. The disappearance of band A indicates 
an amorphous phase formation. Peaks B shifted to lower wavelengths, become much broader, 
and less resolved, suggesting a change in coordination environment. The disappearance of the 
well resolved peaks C could be interpreted as a proof of trimesate release. The band D which 
was broadened but did not disappear could be ascribed to symmetric and asymmetric stretching 
vibrations of Fe–O–P bonds, strongly indicating the formation of phosphate complexes by 
coordination with phosphate ions 32. This is also in agreement with the disappearance of peak 
F in the eroded region II, indicating that coordinated water faded away.  
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Fig.3 Raman spectra of a single microMOFs particle of around 50 microns before (brown) and 
after (red and blue) degradation for 8 days in PBS (11.9 mM). Raman spectra were recorded on 
the same particle, both in the red core (region I) and in the degraded grey shell (region II).  
In conclusion, Raman spectra gave useful insights regarding MOF degradation in PBS, 
suggesting that the most probable degradation mechanism is the competitive replacement of 
trimesate by phosphate ions in PBS solution. Advantageously, Raman microscopy enabled 
obtaining spectra in different regions on the same particle. To gain further insights on the 
degradation mechanism, single particles were tracked over their degradation in PBS during 8 
days.  
Automated imaging was used to gain a deeper understanding of the kinetics of the degradation 
process of each selected particle, since it can provide a direct measurement of the size, shape, 
color, surface area, and circularity of each particle. Images were captured every half an hour 
during 8 days to track the degradation process. Selected images illustrate the typical 
morphologies of one single particle during degradation (Fig. 4). Although shells (eroded zones) 
with a grey color were clearly formed and progressively penetrated into the particles, no 
significant variation in size could be detected. 
Additionally, the variation of mean intensity and surface area was also investigated. Mean 
intensity is a precise parameter to evaluate the color of a particle, based on the amount of light 
reflected by a particle. The darker the particle, the less is the reflected light, resulting in lower 
intensities. Figure 4 shows a sharp increase in the intensity of a MOF particle in the first 6 
hours, indicating a rapid color change, which was too subtle to be observed by the naked eye. 
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This fast phase was followed by a slower increase in mean intensity, accompanied by no 
detectable surface area variation (Fig. 4, progressive phase).  
 
Fig.4 Kinetic study of the degradation of a microMOFs (size around 50 µm in length) in PBS 
(11.9 mM) at room temperature. Particle surface area and mean intensity were recorded each 
30 min up to 8 days. A fast degradation phase was observed in the first 6 hours with a rapid 
increase in mean intensity. A second phase occurred in the following 8 days with the formation 
of an eroded zone with a clear color change (progressive phase). 
It can be speculated that in the first hours after incubation, a fast coordination reaction occurred 
between phosphates in the incubation medium and accessible iron sites at the MOF surface. 
This phase was followed by a slower diffusion of phosphates in the eroded region. The 
advancement of the degradation front was presumably limited by the diffusion of the reacting 
species (phosphates) from the media into the MOFs and by the diffusion of released trimesate 
out of the matrix. 
Mössbauer spectrometry 
57Fe Mössbauer spectrometry was applied to MIL-100(Fe) particles to probe several chemical 
features of interest, such as the Fe oxidation state, the type of Fe species, the possible presence 
of Fe-containing phases different from of MIL-100(Fe) and any Fe oxide resulting from 
degradation. Mössbauer spectra were recorded at 300 and 77K with different velocities and 
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only typical Mössbauer ones are illustrated in Fig. 5. The hyperfine structures result essentially 
from the presence of quadrupolar components. The refined values of the isomer shift indicate 
unambiguously the presence of only high supersaturation (HS) Fe3+ species whatever the 
sample (nano-and microMOFs) and their degradation state. It could be concluded that no Fe 
reduction phenomenon occurred in PBS.  
At 300K, the hyperfine structures of the nano-and microMOF samples after degradation was 
modified (Fig. 5). Before degradation, the spectrum was well described by means of 3 
quadrupolar components (Fig. 5), in agreement with the crystallographic MIL-100(Fe) 
structure, while after degradation, quadrupolar doublets with broadened lines were observed. 
The best physical description requires a discrete distribution of quadrupolar doublets suggesting 
a structure close to that of a typical amorphous structure. The Mössbauer spectra recorded at 
77K are similar to those obtained at 300K at low velocity scale and their corresponding 
hyperfine structures confirm previous conclusions (Fig.S2). A deep analysis of the 12 mm/s 
spectra at 77K allows a small magnetic component (estimated at about 2% in at Fe) to be 
observed, as displayed on the insets of Fig.S2, where relative transmission scale has been 
strongly extended. It corresponds clearly to hematite in the case of the degraded microMOFs 
while it could be attributed to poorly crystallized hematite (including traces of ultra-fine grains 
of goethite). Taking into account the presence of phosphates in the media surrounding the 
microMOF, it is plausible that a highly disordered FeP based skeleton phase was formed, 
corroborating our previous hypothesis. 
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Fig. 5. Mössbauer spectra of nano-and microMOF obtained at 77 K and at 300K. Spectra of 
degraded nanoMOF (Dnano) and microMOF (Dmicro) obtained at 300K. 
Energy dispersive X-ray analysis (EDX) was performed in order to obtain the Fe/P ratios of the 
intact MOFs, half degraded microMOFs, and totally degraded microMOFs. The results showed 
that there is a significant reduction of Fe/P ratios from 1000 (intact MOFs) to 7.6 (half degraded 
microMOFs) and 0.9 (totally degraded microMOFs), confirming that P was coordinated inside 
the porous MOF structures.   
To demonstrate the progressive coordination of phosphates during the degradation process, 
Infra-Red (IR) spectroscopy was performed out on micro-MOFs at different degradation times 
(see Fig. S3). In addition to the decrease in intensity of the carboxylate stretching bands at ca. 
1390 and 1580 cm-1, one could observe the progressive increase of intensity of the phosphate 
bands centered at 1050 cm-1. Although one cannot exclude that amorphous Fe oxide is also 
formed during the degradation process, this confirms the progressive incorporation of 
phosphates throughout of the particles when dispersed into PBS. The broadness of the 
phosphate bands is also in agreement with the amorphous character of the degradation product. 
MOF stability during drug loading  
Gem-MP has been successfully loaded in MIL-100(Fe) MOFs, following the previous 
methodology, which acted as efficient “nanosponges”, soaking the drugs from their aqueous 
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solutions to reach within minutes unprecedented amounts (up to 30 wt%) of drug with loading 
efficiencies higher than 98%24. This is due to the coordination of the phosphate group of the 
drug on the Fe metal sites. In this study, the results from Gem-MP quantification by HPLC 
showed a high payload of 25 wt%. It is therefore important to investigate if drug loading induces 
a degradation of the MOF structure as it was the case when the MOFs were incubated in the 
presence of phosphates in PBS.  
The drug loaded particles were studied by Raman microscopy. Gem-MP did not present 
characteristic Raman peaks in the studied region, facilitating the studies. Fig. 6 does not reveal 
any significant differences in the MIL-100(Fe) microMOFs Raman spectra before and after 
drug loading. These studies are in agreement with HPLC investigations, showing less than 2% 
of loss of the constitutive trimesate. Of note, the microMOFs maintained their crystalline 
structure after Gem-MP loading24. In a nutshell, the MOF 3D structure was maintained after 
drug loading with no impact of the drug on the MOF long-range or local structure. 
 
Fig.6 Effect of loading of Gem-MP in MIL-100(Fe) on the Raman spectra of the particles. 
MOFs particles before (red) and after (purple) Gem-MP loading.  
Previously we showed that MOFs immersed in PBS degraded with kinetics dependent upon the 
phosphates concentration. When Gem-MP was loaded in MOFs at the maximum payload of 30 
wt%, the equivalent amount of phosphates was 0.038 mM, whereas the molar ratio P/Fe was 
only 0.38, which could explain why MOFs did not degrade during drug entrapment. 
MOF stability during coating 
Cyclodextrins (CDs) bearing several phosphate anchoring groups (CD-P) were successfully 
used to functionalize the surface of MOF particles33. Taking advantage of the fact that the size 
of CD-P is larger than the MIL-100(Fe) windows (Fig. 7) the coating could be achieved by a 
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simple way consisting in incubating the MOFs with CD-P in water. This “green” method 
allowed the formation of CD-P shells within minutes and the coating was stable, even in 
biological media33, due to the cooperative coordination between phosphates on CD-P and Fe 
sites at the MOF’s surface. 
 In this study, CD-P coatings were produced on microMOFs following the previous protocol33. 
As reported in the previous work33, elemental analysis was used to evaluate the coating efficacy 
of grafting CD-P, showing that around 17 wt% of CD-P was associated to the MOFs. The 
particles, before and after coating, were studied by Raman microscopy. Of note, CD-P did not 
present any specific peak in the observed region. It was found that after coating, the particles 
maintained same morphology, color and Raman spectra, indicating that CD-P surface 
modification did not induce particle degradation. Similarly as in the case of drug loading, the 
P/Fe ratio in CD-P coated microMOFs was lower than 1 (only 0.6), which could explain why 
the microMOFs did not degrade after coating. The good stability of the particles after CD 
coating offer thus promising possibilities to load drugs of interest and graft ligands for targeting 
purposes. 
 
Fig.7 Raman spectra of individual MIL-100(Fe) MOF particles, coated or not with P-CD. 
Schematic representation of the coating procedure (A) and experimental results (B) for MOF 
particles before and after CD-P coating.   
Conclusion 
Whatever their size, MIL-100(Fe) MOFs degrade in PBS losing their constitutive trimesate 
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linkers and eventually became amorphous with a clear impact of the phosphate concentration 
and the particle size: the higher the phosphate concentration and the lower the particle the faster 
the degradation of the MOF particles. Interestingly, nano-and microMOFs both kept their initial 
sizes during degradation but transformed into inorganic edifices. Raman microscopy enabled 
gaining insights on the degradation mechanism and showed that intact cores were separated 
from the eroded regions by clearly visible erosion fronts. Iron phosphates were identified by 
Mössbauer spectrometry (and IR spectroscopy) as main components in the eroded regions. In 
contrast, neither drug entrapment and nor particle coating did affect the integrity of the 
tridimensional MOF network due to the more diluted conditions. These findings are of interest 
in the development of stable drug-loaded MOF particles. Further studies will be focused on the 
degradation of other engineered MOF materials of interest in biomedicine.  
Materials and Methods  
Chemicals. Iron (III) chloride hexahydrate (98%, Alfa Aesar, Schiltigheim, France), 1,3,5-
benzenetricarboxylic acid (BTC, 95%, Sigma-Aldrich, Saint-Quentin-Fallavier, France) and 
absolute ethanol (99%, Carlo Erba, Val-de-Reuil, France) were used for MOF synthesis. PBS 
(11.9 mM, pH 7.4 ± 0.1) was purchased from Life Technology Co., Ltd.  (Saint Aubin, France). 
It contains 11.9 mM phosphates, 137 mM NaCl and 2.7 mM KCl. Gem-MP (CH12F2N3OP) was 
purchased from Toronto Research Chemicals, Canada. Phosphated β-cyclodextrin sodium salt 
(CD-P, Cyclolab, CY-2017.1, molecular formula: C42H70O47P4Na4) was used for coating. Milli-
Q water was obtained from a Millipore apparatus equipped with a 0.22μm filter. Reagents and 
solvents were used without further purification.  
Nano-and micro-MOFs synthesis. MIL-100(Fe) iron trimesate nanoMOFs were synthesized 
by adapting a previously described method1. Briefly, nanoMOFs were obtained by microwave-
assisted hydrothermal synthesis from a mixture of iron chloride (8.97 mmol) and BTC (4.02 
mmol) in 20 mL of deionized water. The mixture was heated for 6 min at 130oC under stirring. 
The power applied was 800 Watts (Mars-5, CEM, US) with a power maximum output 1,600 ± 
240 Watts and frequency at full power 2,450 mHz. The resulting nanoMOFs, recovered by 
centrifugation, were washed with absolute ethanol 6 times to remove the residual non reacted 
organic acid. A last centrifugation at 5500 g was performed during 1 min in absolute ethanol 
to sediment the largest particles and recover the supernatants as a suspension of monodisperse 
nanoparticles. Nanoparticles were stored wet in ethanol until final use. 
To prepare microMOFs, a reaction mixture composed of 2.7 g iron (III) chloride hexahydrate 
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(10.00 mmol) and 2.1 g trimesic acid (10.00 mmol) in 50 mL of water, was placed in a large 
Teflon bomb under magnetic stirring for 15 minutes. The Teflon reactor was encased in a metal 
bomb with controlled pressure, before being placed in an autoclave with a 1 hour heating ramp 
to 130 °C, and held at this temperature for 72 hours. The product was then cooled before being 
filtered and was then washed by heating under reflux, first in 700 mL of ethanol at 75 °C for 2 
hours and finally in 700 mL of water at 90 °C for 2 hours. The product was then collected by 
filtration under vacuum and stored as powder after being dried in air. 
MOFs characterization. The crystallinity and purity of MIL-100(Fe) particles were assessed 
by PXRD patterns which were collected in a conventional high resolution (-2) D5000 Bruker 
diffractometer (Cu K, K2) from 1º to 20º (2) using a step size of 0.02º and 4° per step in 
continuous mode. The morphologies of microMOFs were investigated by Raman microscopy 
(Malvern® Morphologi G3-ID). Briefly, optical images of more than 2000 particles were 
captured and statistical analysis of size and circularity were carried out. 
Dynamic light scattering (DLS) and Nanoparticle tracking analysis (NTA) were performed by 
a Zetasizer (Malvern® Nano-ZS90) and Nanosight (Malvern® LM10), to characterize the size 
distribution of nanoMOFs. Zeta potential of nanoMOFs was characterized by a Zetasizer 
(Malvern® Nano-ZS90). Nanosight analysis is a combination of a conventional optical 
microscope and a laser to illuminate the nanoparticles introduced into the visualizing unit with 
a 1.0 mL syringe system. Individual particles could be visualized as point-scatter moving under 
Brownian motion. Measurements were performed for 5 times over a period of 60 s at 25°C. The 
particle size and concentration were analyzed using the NTA software. Transmission electron 
microscopy (TEM) images for nanoMOFs were collected using a JEOL® JEM-2200FS 
microscope. The circularity of nanoMOFs was obtained from TEM images and analyzed by 
Origin 9.0 software.  
Statistical analysis of MIL-100(Fe) degradation. The size distribution and morphology of 
MOFs after degradation in PBS were characterized. Briefly, Raman microscopy was applied 
for microMOFs to investigate their size and circularity before and after incubation in PBS (11.9 
mM) for 8 days. TEM was used for nanoMOFs to observe the morphological variation after 
incubation in PBS (1.19 mM) for 6 hours. DLS was used to characterize the mean diameter 
variation during degradation of nanoMOFs in PBS with different concentrations (11.9 mM, 
1.19 mM and 0.12 mM).  
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HPLC determination of the Gem-MP loading and trimesate release. The detection of Gem-
MP and trimesate was carried out in HPLC (Agilent 1100, USA) connected to a Phenomenex 
C18 column (4.6 × 250 mm, 5 µm) at a flow rate of 1.0 mL/min. For the analysis of Gem-MP,   
a mobile phase consisting of 84% buffer (0.2M TEAA):16% MeOH was used. It was detected 
at 254 nm with an injection volume of 20 µl. Analysis of trimesate was performed with a mobile 
phase containing 90% buffer (5.75 g/L of NH4H2PO4): 10% Acetonitrile (5 mM TBAP). The 
injection volume was 5 µl and the detection wavelength was set at 220 nm.  
Individual analysis of MIL-100(Fe) degradation. Individual particles were observed by 
Raman microscopy and Raman spectra were obtained for degraded and non-degraded particles. 
Microparticles were kept in PBS (11.9 mM) for 8 days under the monitor of Raman microscopy. 
Images were captured every 30 min to track the degradation process using automated imaging. 
Surface areas and intensity mean were extracted from the software and kinetic analysis was 
carried out in function of surface areas and intensity mean. Raman spectra were recorded at the 
laser wavelength of 785 nm. The laser spot was 3 μm in diameter with power output as 15 mW.  
Transmission 57Fe Mössbauer spectrometry was performed using a conventional 
electromagnetic transducer with a constant acceleration and a 57Co/Rh γ-ray source.  Mössbauer 
spectra were recorded at 300 K and 77 K using a bath cryostat on samples which consist in a 
powdered layer containing about 5 mg of Fe/cm2. The hyperfine structure was modeled by a 
least-square fitting procedure involving quadrupolar doublets and/or Zeeman sextets composed 
of lorentzian lines using unpublished program ‘MOSFIT’. The isomer shift values (IS) are 
referred to that of -Fe at 300 K, used as a standard to calibrate the spectrometer. 
EDX analysis. The chemical compositions of the samples were determined by EDX performed 
on a FEI Magellan 400 Scanning Electron Microscope. Three samples were analyzed: i) intact 
MOFs; ii) half degraded microMOFs; iii) totally degraded microMOFs. Twelve spectra were 
obtained for each sample and the content of P, Fe, and Cl was calculated by getting the average 
of the 12 spectra. Finally, Fe/P ratios were calculated for each sample.   
PXRD analysis. PXRD patterns were collected in reflection mode using a PANalytical 
Empyrean Series 2 diffractometer with an average wavelength of 1.541 Å Cu Kα (45 kV and 
40 mA). Measurements were performed at room temperature between 3° and 100° in 2θ, using 
a step size of 0.026° step, and a counting time per step of 200 s. 
Investigation of drug loaded MIL-100(Fe). Gem-MP was loaded in microMOFs by adapting 
a previously described method 24. Briefly, MOFs in ethanol were re-dispersed in water under 
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gentle magnetic stirring overnight. Then Gem-MP loaded MOFs were prepared by soaking for 
one week microMOFs in Gem-MP aqueous solution (0.5 mg/mL) using a weight ratio 1:2 
(Gem-MP: microMOFs) to reach maximal loadings of 30 wt%. Afterwards, Raman spectra of 
Gem-MP loaded MOFs were obtained by Raman microscopy. 
Investigation of CD-P coated MIL-100(Fe). MIL-100(Fe) MOFs were coated with CD-P as 
previously described33. Briefly, MOFs were suspended in a CD-P aqueous solution under gentle 
stirring at room temperature for 24 hours. The initial MOFs/CD-P weight ratio was 1:0.5, and 
the final MOFs concentration was 4 mg/mL. The coated MOFs were recovered by 
centrifugation (5000 g for 5 min) and were washed with deionized water in order to remove the 
excess CD-P which was not associated to the MOFs surface. Finally, Raman spectra and images 
of CD-P coated MOFs were recorded by Raman microscopy. 
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Supplementary Methods 
Trimesate release from nanoMOFs in PBS. NanoMOFs were incubated in PBS (11.9 mM, 
1.19 mM and 0.12 mM) at 37°C. The samples were centifugated and the amount of trimesate 
in the supernatant was assessed by HPLC. Analysis of trimesate was performed with a mobile 
phase containing 90% buffer (5.75 g/L of NH4H2PO4): 10% Acetonitrile (5 mM TBAP). The 
injection volume was 5 µl and the detection wavelength was set at 220 nm. As controls, MOFs 
were incubated in water instead of PBS under the same conditions and trimesate release was 
monitored.  
PXRD analysis. The crystallinity and purity of MIL-100 (Fe) nanoMOFs before and after 
degradation were assessed by PXRD. PXRD patterns were collected using a high resolution (-
2) D5000 Bruker diffractometer (Cu K, K2) from 1º to 90º (2) using a step size of 0.02º 
and 4° per step in continuous mode. Four samples were used for the analysis: i) intact 
nanoMOFs; ii) totally degraded nanoMOFs after incubation in PBS (11.9 mM) for 4 h; iii) half-
degraded microMOFs after incubation in PBS (11.9 mM) for 3 days, and iv) totally degraded 
microMOFs after incubation in PBS (11.9 mM) for 1 month. 
Fourier transform infrared spectroscopy (FTIR) analysis. 100 mg of microMOFs were 
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incubated in 50 mL of PBS (11.9 mM) at 37 °C with stirring speed at 100 rpm. The samples 
were collected by centrifugation after incubation for 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 3 d, 5 d, and 
7 d. The samples were dried at 100°C overnight. IR spectra were recorded in KBr disk on a 
Nicolet 205 FTIR. 
Supplementary Results 
NanoMOFs degraded quickly in concentrated PBS (11.9 mM), with their crystallinity lost (Fig. 
S1) and 32 ± 3.0 wt % of trimesate released after 4 hours incubation (Table S1). When PBS 
was diluted to 1.19 mM, it took 6 hours to get totally degraded, releasing 34 ± 2.6 wt % of 
trimesate. NanoMOF can also be degraded even in extremely diluted PBS (0.12 mM), releasing 
31 ± 2.8 wt % after two days incubation. Whereas, there was no degradation observed in water 
after 2 days incubation, with less than 2 wt % of their trimesate released and the crystallinity 
well preserved. 
Table S1. Trimesate release of nanoMOF in PBS (11.9 mM, 1.19 mM, and 0.12 mM) and in 
water during incubation at 37°C. 
 
PBS concentration (mM) Incubation time (h) Trimesate release (wt%) 
11.9 4 32 ± 3.0 
1.19 6 34 ± 2.6 
0.12 48 31 ± 2.8 
0 (water) 48 ≤ 2 ± 0.2 
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Fig. S1. PXRD pattern of intact nanoMOFs (black), totally degraded nanoMOFs (green), half-
degraded microMOFs (red), and totally degraded microMOFs (blue). 
The Mössbauer spectra at 77K of degraded nanoMOF and microMOF are illustrated in Fig. S2. 
Experiments were performed at 2 and 12 mm/s. The low velocity scale spectra are similar to 
those obtained at 300K and their corresponding hyperfine structures confirm previous 
conclusions. A deep analysis of the 12 mm/s spectra at 77K allows a small magnetic component 
(estimated at about 2% in at Fe) to be observed, as displayed on the insets of Fig.S2, where 
relative transmission scale has been strongly extended. It corresponds clearly to hematite in the 
case of the degraded microMOFs while it could be attributed to poorly crystallized hematite 
(including traces of ultra-fine grains of goethite). 
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Fig. S2 Mössbauer spectra at 77K of degraded nanoMOF and microMOF 
Energy dispersive X-ray analysis (EDX) was performed in order to obtain the Fe/P ratios of the 
intact MOFs, half degraded microMOFs, and totally degraded microMOFs. The results showed 
that there is significant reduce of Fe/P ratios from 1000 (intact MOFs) to 7.6 (half degraded 
microMOFs) and 0.9 (totally degraded microMOFs), confirming that P was coordinated inside 
the amorphous matrices of MOF structure during the degradation process. 
Table S2. Fe/P ratios of the intact MOFs, half degraded microMOFs, and totally degraded 
microMOFs. 
Type of MOFs Fe (%) P Fe/P 
intact 92.55 ± 1.43 0.09 ± 0.41 ~ 1000 
Half-degraded 74.94 ± 3.10 9.89 ± 3.64 ~ 7.6 
Totally degraded 42.60 ± 11.98 44.57 ± 13.26 ~ 0.9 
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Fig. S3 FTIR spectra of microMOFs during their degradation in PBS 
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Subchapter 4.2 
Two drugs in two different mesoporous cages inside the same nanoparticle:  
design and applications 
 
In preparation 
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General Objectives and Author Contributions 
Because of their high pore volumes and surface areas, MIL-100 (Fe) was shown to load a series 
of drugs, such as antibiotics and anticancer drugs, which are able to efficiently penetrate within 
the porous MOF structures. However, to the best of our knowledge, there is no report on 
synergic drugs co-encapsulation in MOF particles yet. Combinatorial drug therapies emerge 
among the most promising strategies to treat complex pathologies such as cancer and severe 
infections.  Herein, Amoxicillin (AMOX) and Potassium Clavulanate (CL), the typical synergic 
antibiotics, were chosen for drug co-encapsulation in MIL-100 (Fe).  
As described before, MIL-100 (Fe) contains two types of cages: small cages (24 Å) with 
pentagonal (5.6 Å) window and large cages (29 Å) with hexagonal windows (8.6 Å). The 
dimension of AMOX (12×9×4 Å) allows it penetrate only within the large cages. CL, with a 
significant smaller dimension (8×5×4 Å) than AMOX, is expected to travel through both the 
large and small cages. Interestingly, AMOX has larger affinity than CL, making it occupy the 
large cages and CL in the small cages.  
Briefly, this study included four parts: 
1) AMOX or CL was encapsulated as single component by by a simple “green” methods, where 
the as-synthesized nanoMOFs were impregnated the in aqueous drug solutions. The 
encapsulated AMOX and CL loadings plateaued at 13 and 27 wt%, respectively. 
2) Co-encapsulation of AMOX and CL was achieved by impregnating the as-synthesized 
nanoMOFs in aqueous drug combination solutions. High payloads for both drugs were 
obtained: 13 wt% for AMOX and 22 wt% for CL, which is quite similar to the individual drug 
loadings. 
3) Molecular simulations showed that each drug located in a separate compartment within the 
interconnected 3D structure of nanoMOFs. 
4) In vitro study on infected macrophages indicated that the drug loaded nanoMOFs were 
efficiently internalized in the cells, and surprisingly, could co-localize with the bacteria and act 
synergistically with the entrapped drugs to kill intracellular bacteria. 
All the authors have contributed in this work. X. Li performed the experiments on the 
nanoMOFs synthesis, characterization and drug loading, and also contributed to the analysis of 
the data and writing of the main manuscript. 
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Abstract 
Combinatorial drug therapies emerge among the most promising strategies to treat complex 
pathologies such as cancer and severe infections. Metal-organic frameworks nanoparticles 
(nanoMOFs) were used here to address the challenging aspects related to the co-incorporation 
of a drug combination. Amoxicillin (AMOX) and potassium clavulanate (CL), a typical 
example of drugs used in tandem, were efficiently co-incorporated with payloads up to 36 wt%.  
Each drug adopted a different penetration pathway to eventually locate in a separate 
compartment within the porous interconnected frameworks. Molecular simulations predicted 
drug loadings and locations and corroborated well the experimental findings. Furthermore, 
nanoMOFs were efficiently internalized in macrophages infected with S. aureus, were found in 
high amounts nearby the pathogen and contributed together with the entrapped drugs to 
eradicate it. These results pave the way towards the design of engineered nanocarriers in which 
both the loaded drugs and their carrier play a role in fighting intracellular infections. 
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 The treatment of complex pathologies such as cancer and severe viral or bacterial infections 
involves taking into consideration multiple molecular and genomic pathways. In this context, 
combinatorial drug therapies are considered among the most effective strategies 1-4 and a recent 
trend is to co-incorporate synergic drugs in nanoparticles (NPs) able to target them to the 
diseased sites. Indeed, nanotechnology revolutionizes drug delivery by achieving: i) drug 
targeting; ii) transcytosis of drugs across biological barriers; iii) delivery of drugs to 
intracellular targets and iv) visualization of sites of drug delivery (theranostics).  
The treatment of intracellular infections is particularly challenging, requiring the drugs to 
bypass cellular membranes to reach their target, the pathogens located in intracellular niches. 
Unfortunately, many drugs poorly penetrate inside cells, necessitating to increase the 
administered doses with might lead to side effects and drug resistance. Ideally, drugs could be 
loaded in NPs, which would act as “Trojan horses” to co-localize with the pathogens and release 
their drug cargo. Amoxicillin (AMOX) and potassium clavulanate (CL) are typical examples 
of drugs used in tandem to treat a variety of bacterial infections, mainly rhinosinusitis, ear 
infections, pharyngolaryngitis, tonsillitis, bronchitis and urinary tract infections5. However, 
these polar drugs are poorly permeable across the cell membranes and lack efficacy in 
intracellular infections.6-8  
There are still few examples of NPs with different compartments engineered for drug co-
incorporation. Anisotropic Janus NPs 9-12, nanocapsules13 and polymersomes14,15 are composed 
of several macroscopic compartments, each one being adapted to accommodate a specific drug. 
Nevertheless, the preparation methods of anisotropic NPs are relatively complex and require 
the use of organic solvents and surfactants. Another example is porous NPs in which drug 
combinations were physically adsorbed16,17. However, as a general trend, when drugs were co-
encapsulated, they impeded each other leading to dramatically reduced loadings. For example, 
the loading of gemcitabine monophosphate in NPs made of coordination polymers was 
drastically reduced from 57 ± 2 wt% to 12 ± 2 wt% when oxaliplatin was co-encapsulated18. 
NanoMOFs based on porous iron (III) trimesate were used here to address the challenge of co-
incorporating drugs with high loadings. NanoMOFs have emerged as a new class of versatile, 
biodegradable and non-toxic drug nanocarriers 19-21.  Because of their high pore volumes and 
surface areas, nanoMOFs were shown to load unprecedented amounts (within the 20-150 wt % 
range) of a series of drugs able to efficiently penetrate within the porous MOF structures 19,20,22-
25 .  
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Here we show that AMOX and CL can be efficiently co-incorporated in nanoMOFs following 
a solvent-free “green” procedure. Each drug was located in a specific compartment inside the 
porous nanoMOF structure, following a distinct incorporation mechanism. Remarkably, 
molecular simulations predicted the location of each drug as well as the maximal loadings, in 
good agreement with the experimental results. Advantageously, a high number of cell-
internalized nanoMOFs were found to co-localize with bacteria and to degrade within hours. 
Contrary to free drugs, drug-loaded nanoMOFs efficiently reduced the intracellular bacterial 
loads, in vitro in a model of macrophages infected with Staphylococcus aureus (S. aureus).  
Results and discussion 
NanoMOFs synthesis and drug incorporation  
NanoMOFs made of non-toxic mesoporous iron (III) trimesate MIL-100(Fe) (MIL standing for 
Material from Institute Lavoisier) are of particular interest for drug encapsulation. MIL-100(Fe) 
nanoMOFs are built up from iron (III) octahedra trimers and trimesate linkers (1,3,5-benzene 
tricarboxylate) that self-assemble to build a porous architecture delimiting two types of 
compartments: large (29 Å) and small (24 Å) mesoporous cages (Fig.1). The two types of cages 
are accessible for drug adsorption inside the crystalline MOF structure through microporous 
pentagonal (~5 Å) and hexagonal windows (~9 Å) 26.  
 
Figure 1. Schematic representation of drug incorporation in nanoMOFs. AMOX, bulkier 
than CL, can only cross the large hexagonal windows, whereas CL can penetrate through both 
pentagonal and hexagonal windows. Therefore, AMOX and CL are prone to locate in large or 
in large and small cages, respectively  
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MIL-100(Fe) nanoMOFs with mean diameters of 273 ± 23 nm and BET surface areas of 1490 
± 100 m2.g-1 were successfully prepared by a solvent-free “green” hydrothermal method. They 
displayed a crystallized structure in agreement with previously reported data22,27 and a facetted 
morphology (Fig. 2a).  
 
Figure 2. Microscopic investigation of nanoMOFs before and after their internalisation in 
J774 macrophages. TEM images of nanoMOFs: empty (a), loaded with AMOX and CL (b) 
and after 4 h degradation in PBS (c). J774 cells before (d, insert) and after (d, black arrows) 
nanoMOF uptake (optical microscopy). TEM images of cellular compartments containing 
nanoMOFs after 1 h (e) and 6 h (f) incubation with cells.  
In a first step, AMOX and CL were encapsulated as single components by impregnating the as-
synthesized nanoMOFs in aqueous solutions of each drug. The molecular dimensions of 
AMOX (12×9×4 Å) (Fig. 1) are very similar to the ones of azidothimidine-triphosphate (AZT-
TP) which was previously shown to exclusively access the large cages of MIL-100(Fe) through 
the hexagonal windows 26. Given its dimensions, AMOX is expected to cross only the large 
hexagonal MOF windows to access the large cages. In contrast, CL, with significant smaller 
dimensions (854 Å) than AMOX (Fig. 1), is able to cross both the pentagonal and the 
hexagonal windows of the interconnected 3D structure allowing the occupancy of both small 
and large mesoporous cages.  
In drug loading experiments, nanoMOFs suspensions were incubated with aqueous drug 
solutions with increasing concentrations to estimate the maximal loadings for each drug (Fig. 
3a). At weight ratios nanoMOF: drug of 32:1, the encapsulation efficiencies (EE) were higher 
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than 98%, showing that the drugs were efficiently soaked by the MOF “nanosponges” from 
their aqueous solutions (for EE calculations see methods I.3). This clearly shows the excellent 
affinity of nanoMOFs for the studied antibiotics and is in line with recent findings showing that 
MOFs can be used to remove trace antibiotics as pollutants in wastewater.  
Maximal AMOX and CL loadings were 13 and 27 wt%, respectively. Even at these maximal 
loadings, the morphology and crystalline structure of the nanoMOFs were unaffected, as 
revealed by: i) identical powder X-ray diffraction patterns before and after encapsulation (Fig. 
S1) and ii) similar shape and facetted morphologies of the pristine and the drug-loaded 
nanoMOFs (Fig. 2b).  
  
Figure 3. (Co)-incorporation of drugs as a function of the NanoMOF: drug ratio used in 
the preparation procedure (green: AMOX; red: CL). (a) Incorporation of individual 
drugs; (b, c) Co-incorporation of AMOX and CL 
The nanoMOFs loaded with maximal amounts of AMOX (13 wt%) had similar mean diameters 
(284 ± 18 nm) as the unloaded ones (273 ± 23 nm). However, an aggregation was observed 
with CL-loaded nanoMOFs at their maximal loading (27 wt%). In this case, the mean diameters 
reached 457±46 nm after CL incorporation. Possibly, a fraction of CL located in the nanoMOF 
top layers induced a bridging effect, leading to their aggregation.  
The proof that the drugs were mainly located inside the nanoMOF cages and not at the external 
surface came from BET experiments. After encapsulation of maximal amounts of AMOX and 
CL, BET surfaces decreased from 1490 m2.g-1 to 994 and 643 m2.g-1 for AMOX and CL at 
maximal loadings, respectively. These findings are consistent with an efficient pore filling by 
the encapsulated molecules, without altering their tridimensional crystalline structure, as 
previously reported with other drugs 10,22,23. 
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Molecular simulations of drug incorporation 
Molecular simulations were performed to gain further understanding on the possible location 
of AMOX and CL and their interactions with the host MOF matrices. Grand Canonical Monte 
Carlo (GCMC) simulations were conducted first to predict the optimal uptake for both drugs as 
single components in MIL-100(Fe), taking into account the NP available porous volume (for 
details see methods I.4).  
The simulated AMOX uptake in the nanoMOFs of 15.5 wt% was in good agreement with the 
experimental data (13 wt%). This is in good agreement with the experimental N2 adsorption 
data which showed that the BET surface area evolved from 1490 m2.g-1 (empty nanoMOF) to 
994 m2.g-1 (nanoMOF loaded with AMOX at their maximal capacity). These data support the 
assumption that AMOX was exclusively incorporated in the large cages of MIL-100(Fe) since 
the volume ratio between large cages and small cages is 1:2.  
Contrary to AMOX (12×9×4 Å), CL, with significant smaller dimensions (854 Å) (Fig. 1), 
is expected to penetrate through the entire MOF 3D structure, allowing the occupancy of both 
small and large mesoporous cages. Indeed, this assumption was confirmed experimentally by a 
drastic reduction of the BET surface after CL incorporation (643 m2.g-1), as compared to 
AMOX-loaded nanoMOFs (994 m2.g-1) and empty ones (1490 m2.g-1). Moreover, the simulated 
CL uptake of 30.6 wt% was in good agreement with the experimental loading of 27 wt%. 
Altogether, these data unambiguously demonstrate that when adsorbed as a single component, 
CL accommodates in both types of MIL-100(Fe) cages.  
Co-incorporation of AMOX and CL 
Furthermore, AMOX and CL were co-incorporated in the nanoMOFs by the same “green” 
strategy used for single drugs and consisting in incubating the nanoMOFs with aqueous 
solutions of both drugs. Extensive studies were carried on, by varying the molar ratio AMOX: 
CL in an attempt to gain insights on the competition between the two drugs for the nanoMOF 
cages. Fig. 3b shows that when AMOX was loaded at 13 wt%, i.e. the maximal nanoMOF 
capacity previously determined for this drug, it was still possible to load additional 22 wt% CL 
in the MOFs. More precisely, Fig. 3b shows that whatever the AMOX content in the nanoMOFs 
(from 2 to 13 wt%), the amount of CL which could additionally be loaded was practically 
constant (20 ± 2 wt%). This overrules the possibility that AMOX impedes CL incorporation in 
the nanoMOFs. Moreover, the AMOX loadings were unaffected by CL loading (13 ± 0.9%, 13 
± 0.8% for AMOX with or without CL). In conclusion, AMOX and CL could be simultaneously 
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loaded without impeding each other. The combinational payload reached at maximum 35 wt%, 
including 22 wt% of CL and 13 wt% of AMOX. 
As in the case of single drugs, co-incorporation of AMOX and CL did not alter the nanoMOF 
crystalline structure (identical X-ray diffraction patterns, Fig. S1) nor their morphology (Fig. 
2b). Interestingly, after co-incorporation of both drugs at their maximal loadings (13 wt% and 
22 wt% for AMOX and CL, respectively) there was less than 10% variation of the mean 
diameters (273 ± 23 nm and 298 ± 9 nm, before and after drug loading, respectively). The 
nanoMOFs loaded with both drugs were stable upon storage and in cell culture media.  
As previously, GCMC simulations were performed to gain insights into the possible locations 
of co-incorporated AMOX and CL. A careful analysis of the GCMC runs evidenced that each 
drugs followed a distinct pore filling mechanism. The AMOX molecules were almost 
exclusively incorporated in the large cages with an uptake of 15.5 wt%, identical to the one 
simulated above in the case of AMOX adsorption as single component. In contrast, CL was 
able to accommodate both small and large cages. Interestingly, almost all the entire fraction of 
the encapsulated CL molecules occupied the small cages with less than 5% CL located in the 
large cages near the windows. The simulated CL uptake in these compartments was 20 wt%, in 
excellent agreement with the experimental results (22 wt%). In conclusion, GCMC simulations 
were a powerful tool to predict the competitive adsorption of AMOX and CL in MIL-100(Fe) 
nanoMOFs. 
Furthermore, the density probability plot reported in Fig. 4 clearly showed that the drugs were 
characterized by totally different distributions inside the MOF. The two distinct preferential 
adsorption regions (AMOX, green and CL, red) suggest independent incorporation 
mechanisms.  
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Figure 4. Density probability plots for AMOX (green) and CL (red) in the cages of MIL-
100(Fe). Data were extracted from the GCMC simulations conducted for the co-encapsulation 
of the two drugs (uptakes of 15.5 wt% and 20 wt% for AMOX and CL, respectively). 
The preferential arrangements of AMOX and CL in the large and small cages, respectively, 
were determined by Monte Carlo simulations (see methods I.4). Figure 5a shows that in the 
large cage, AMOX adapted its conformation to establish relatively strong interactions with the 
cage walls, displaying several interacting pairs characterized by distances below 3.0 Å. More 
precisely, the carbonyl and the hydroxyl functions of AMOX interacted with the Fe metal sites 
and the carbonyl groups of the MIL-100(Fe) framework, respectively. As illustrated in Fig.5b, 
CL showed similar interactions as AMOX with the small cage walls, although this molecule 
contains a lower number of active sites as compared to AMOX. The calculated interacting 
distances were significantly longer, suggesting a weaker host/drug interaction. These results 
were confirmed by simulated adsorption enthalpies, which were in the rage of -224 kJ/mol and 
-150 kJ/mol for AMOX and CL, respectively. In a nutshell, simulation studies clearly 
demonstrated that AMOX has a stronger affinity than CL for the MIL-100(Fe) framework. This 
supports the previous experimental findings, which showed that once incorporated in the large 
cages, AMOX couldn’t be displaced by CL, a drug with lower affinity than AMOX for the 
nanoMOFs. 
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Figure 5. Preferential geometries of AMOX (a) and CL (b) in the large and the 
small mesoporous cages of MIL-100(Fe), respectively. Calculations were issued from Monte 
Carlo simulations performed with one drug molecule per cage. For clarity reasons, the 
hydrogen atoms of the framework are not represented. The characteristic drug/MOF interacting 
distances are reported in Å. 
Given the capacity of MIL-100(Fe) nanoMOFs to incorporate high amounts of both AMOX 
and CL (total loading 35 wt%), these nanocarriers were further studied in vitro on infected cells 
to test their antibacterial properties. 
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Uptake of nanoMOFs by macrophages and effects on intracellular S. aureus  
S. aureus possesses several virulence mechanisms to accommodate a diversity of niches. On 
one side, S. aureus can be the production of toxins that favor cell lysis and tissue destruction in 
acute infections. On the other side, it can invade and survive in host cells such as epithelial 
cells, osteoblasts, neutrophils or macrophages and be responsible for chronic infections. Indeed, 
several main antibiotics such as β-lactams and aminoglycosides lack of efficacy to eradicate 
intracellular pathogens 26,28,29, as they can poorly bypass cell membranes and/or are rapidly 
cleared off by efflux pumps (Fig. 6a). Contrary to free drugs, nanoMOFs are able to efficiently 
penetrate inside infected macrophages and to release their drug cargo near pathogens could be 
powerful alternatives to treat intracellular infections 26,30,31. The ability of nanoMOFs loaded 
with AMOX and CL to address this important goal was tested here. Firstly, the cytotoxicity of 
nanoMOFs at various concentration was tested (data not shown). The nanoMOFs were found 
to be non-cytotoxic in J774 macrophages at concentrations up to 50 µg/mL. Indeed, after 24 h 
of contact with nanoMOFs, cell viability was higher than 90%. The internalization of 
nanoMOFs by macrophages was studies at concentration of 25 µg/mL. 
Efficient internalization of nanoMOFs is crucial to eliminate intracellular pathogens. The 
presence of nanoMOFs was first confirmed by optical microscopy investigations (Fig. 2d). It 
was found that nanoMOFs were efficiently taken up by J774 cells, mainly by phagocytosis and 
in a lesser extent by a clathrin-dependent pathway (Fig. S2). In agreement with these findings, 
a large number of nanoMOFs were found in endosomal or/and phagolysosomal compartments 
of non-infected cells (Fig. 2e). After 6 h incubation, the nanoMOFs degraded inside these 
compartments, showing a blurry transparent structure (Fig. 2f) similar to the previous one 
reported in in vitro degradation studies in PBS32.  
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Figure 6. The internalization of drug loaded nanoMOFs in infected macrophages and 
their antibacterial effects. Schematic representation (a); TEM images of J774 macrophages 
showing nanoMOFs co-localized with S. aureus after 1 h incubation (b, red arrows) and 
partially degraded after 6 h (c, red arrows); Antibacterial effects of free AMOX, empty and 
drug-loaded nanoMOFs on S. aureus (ATCC55585) (d) and of AMOX and CL on a clinical 
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penicillin-resistant S. aureus (e).   
Finally, we investigated the effect of nanoMOFs on intracellular S. aureus in in vitro cell 
infection models using J774 murine macrophages. Cells were first pre-incubated with 
nanoMOFs, loaded or not with drugs, during 2 h. Then, cells were washed and infected with S. 
aureus for 2 h. At the end of the infection time, extracellular bacteria were eliminated and cells 
were incubated with gentamicin for 1 h or 6 h. This experimental protocol allowed us to focus 
on killing of intracellular staphylococci by internalized nanoMOFs without dealing with what 
happens in the extracellular environment. First, we evaluated the effect of empty nanoMOFs 
and AMOX-loaded nanoMOFs on penicillin-susceptible S. aureus ATCC 55585. As we 
observed on TEM images, several nanoMOFs were found to co-localize with intracellular S. 
aureus in the phagosomes of infected cells, even after 1h post incubation (Fig. 6b). After 6 h 
incubation, intracellular nanoMOFs structure became blurred indicating their degradation as it 
was observed in non-infected cells (Fig. 2f, Fig. 6b). Quantification of intracellular 
staphylococci reported a decrease of 80% after 6h incubation with AMOX-loaded nanoMOFs. 
As expected, free AMOX known to poorly penetrate inside the cells33,34 had no effect on 
intracellular bacteria. Interestingly, a decrease of intracellular bacteria number was also 
reported with empty nanoMOFs (Fig. 6d). The bactericidal effect of this cell-internalized free 
nanoMOFs was reported proportional both to the amount of nanoMOFs initially in contact with 
the cells and the incubation time (Fig.S3). A significant bactericidal effect of empty nanoMOFs 
was observed when the amount of nanoMOFs initially in contact with the cells was higher than 
12.5 μg/mL and after 6 h of incubation.  
To confirm our results and test the co-encapsulation biologic activities, we evaluated the 
intracellular efficacy of nanoMOFs loaded with AMOX and CL on a clinical penicillin-resistant 
S. aureus. We still observed a decrease of the number of intracellular staphylococci with empty 
nanoMOFs, but this effect was not significantly enhanced by the incorporation of AMOX or of 
AMOX and CL (Fig. 6e). Experiments with longer incubation times (up to 24 h) gave similar 
results. The antibacterial effect of empty nanoMOFs on intracellular bacteria overwhelmed that 
of the incorporated drugs. Of note, nanoMOFs had no direct effect on S. aureus (MIC > 250 
µg/mL). Further studies will be needed to decipher the bactericidal effect of nanoMOFs which 
could be related to reactive oxygen species (ROS) production 35,36, without toxic effects of the 
J774 macrophages.  
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Conclusion  
Here we showed for the first time that two drugs can be efficiently incorporated in MOFs, each 
one being preferentially adsorbed in the large or small mesoporous cages. The drugs followed 
individual incorporation mechanisms without impeding each other, resulting in total loadings 
as high as 35 wt%. Molecular modelling corroborated well the experimental findings and 
predicted the preferential location of each molecule. It was discovered that, nanoMOFs were 
prone to co-localize with intracellular pathogens and had an intrinsic bactericidal action, 
contributing, together with the incorporated drugs, to reduce the bacterial loads. These results 
pave the way towards the design of engineered NPs in which each component (drugs and 
nanocarrier) plays a role in fighting intracellular infections.  
Methods 
Methods, including statements of data availability and any associated accession codes and 
references, are available. 
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Materials and Methods 
I.1 Materials 
Chemical materials. Iron (III) chloride hexahydrate (98%, Alfa Aesar, Schiltigheim, France), 
1,3,5-benzenetricarboxylic acid (BTC, 95%, Sigma-Aldrich, Saint-Quentin-Fallavier, France) 
and absolute ethanol (99%, Carlo Erba, Val-de-Reuil, france) were used for the synthesis of 
nanoMOFs. AMOX and CL were purchased from Sigma-Aldrich. All the chemicals were used 
without further purification.  
Cell culture. Murine macrophages J774 were grown in RPMI-1640 medium (BioWhittaker, 
Walkerville, MD, USA) supplemented with 10% v/v decomplemented fetal bovine serum 
(FBS) (Cambrex BioSciences, Verviers, Belgium) at 37°C in humidified air containing 5% 
CO2. Lactate dehydrogenase leakage (LDH, Sigma-Aldrich) were used for toxicity evaluation 
of nanoMOFs. 
NanoMOFs internalization assay. Cytochalasin D 5µg/mL, Latrunculine A 400 nM, 
Wortmannin 300 nM, Chlorpromazine 20 µM, Ikarugamycin 4 µM, methyl-β-cyclodextrin 
(Mβ-CD 1 mM, Genistein 100 µM, Fillipin III 1 µM (Sigma-Aldrich) were used as 
pharmacological inhibitors to investigate the nanoMOF mechanisms of cell internalisation. 
Tiron (Sigma-Aldrich) was used to inhibit the ROS effect. Prussian blue staining (Sigma-
Aldrich) was used as Iron staining kit to visualise the intracellular nanoMOFs. 
Bacterial culture. The beta-lactam sensitive S. aureus (ATCC55585) stock strains were 
maintained in 20% glycerol at -80°C. Before experiments, the bacteria were transferred onto 
fresh Brain Heart Infusion (BHI)/ agar (Difco, Invitrogen, Cergy-Pontoise, France) and 
incubated at 37°C for 24 h. For each experiment, bacteria were subcultured in BHI (medium) 
at 37°C for 18 h. The day of the experiment, the bacteria were washed twice with sterile PBS, 
counted in a Salumbini chamber, and adjusted to 5×106 bacteria/mL in RPMI-1640 medium 
supplemented with 10% v/v FBS. 
I.2 MIL100 (Fe) nanoMOFs synthesis and characterization 
NanoMOFs synthesis. MIL100 (Fe) iron trimesate nanoMOFs were synthesized by adapting a 
previously described method26. Briefly, nanoMOFs were obtained by microwave-assisted 
hydrothermal synthesis from a mixture of iron chloride (8.97 mmol) and BTC (4.02 mmol) in 
20 mL of deionized water. The mixture was heated 6 min at 130oC under stirring. The power 
applied was 400 Watt (Mars-5, CEM, US) with a power maximum output 1,600 ± 240 Watts 
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and frequency at full power 2,450 mHz. The resulting nanoMOFs were recovered by 
centrifuging 10 min at 10,000 ×g and washed with absolute ethanol 6 times to remove the 
residual non reacted organic acid. A last centrifugation at 5500 ×g was performed during 1 min 
in absolute ethanol to sediment the largest particles and recover the supernatants as a suspension 
of monodisperse nanoparticles. NanoMOFs were stored wet in ethanol until final use. 
NanoMOFs characterization. The cristallinity and purity of MIL-100  (Fe) nanoMOFs were 
assessed by X ray powder diffraction (XRPD) patterns which were collected in a conventional 
high resolution (θ-2θ) D5000 Bruker diffractometer (λCu Kα, Kα2) from 1º to 20º (2θ) using a 
step size of 0.02º and 4° per step in continuous mode. The size distribution and Zeta potential 
of nanoMOFs were characterized by dynamic light scattering (DLS; Malvern® Nano-ZS) 
nanosight (NTA, LM10 Nanosight), and using a Zetasizer (Malvern® ZSP, UK) respectively. 
Nanosight analyses combines a conventional optical microscope with a laser to illuminate 
nanoparticles in Brownian motion. Particles could be visualised one by one as moving point-
scatters. Each measurement was repeated 5 times, at room temperature. The particle size 
distribution was determined using the NTA software. 
Transmission electron microscopy (TEM) images were collected in a Darwin 208 Philips 
microscope (60-80-100 KV; Camera AMT). The nanoparticles porous surface was measured 
by nitrogen sorption experiments at -77 K on a ASAP 2020 (Micromeritics) after sample’s 
outgassing at 150°C for 18 h under secondary vacuum.  
I.3 Drug incorporation 
Drugs were loaded within MIL-100 (Fe) nanoMOFs simply by impregnation of well defined 
amounts of nanoMOFs and drug(s) solutions in water. Practically, 1 or 4 mg of nanoMOFs 
were centrifuged for 10 min at 10,000 g and re-suspended in 1 mL of aqueous drug solutions 
(concentrations from 0.125 to 1 mg/mL) or water as a control. After incubation for 12 h under 
gentle stirring, the nanoMOFs were recovered by centrifugation (10,000×g, 10 min) and the 
non-encapsulated drug in the supernatant was quantified by adapting a previously described 
HPLC method37. Specifically, HPLC analysis was performed on a WatersTM system using a 
WatersTM 486 tunable UV absorbance detector. Eluant flowed at a rate of 0.5 mL/min through 
a C18 Silica 150 × 3.0 mm column (Interchim, Montluçon France) maintained at 30°C. The 
injection volume was 20 μL which ran for 8 min after each injection. The mobile phase 
consisted of 5.2 g/L of sodium dihydrogene phosphate monohydrate in 30% (v/v) methanol. 
The pH was adjusted to 5 using dilute ortho-phosphoric acid solution. CL and AMOX were 
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detected at 247 nm and retention times were 2.1 and 4.6 minutes, respectively. 
The encapsulation efficiency (EE) was calculated as Equation (1): 
  100
)(
 )(
(%) 
mgrug Initial  D
mged  Drug Encapsulat
EE                                                      (1) 
where “encapsulated Drug” represents the amount (mg) of drug incorporated in nanoMOFs and 
“Initial drug” represents the amount (mg) of drug initially added in the experiment. 
The drug payload was calculated as Equation (2):  
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Drug release was studied in different media (water, cell culture media). After incubation at 
37°C during different lapses of time, nanoMOFs were recovered by centrifugation (10 min, 
10000×g) and supernatants were assessed by HPLC to determine the amounts of released 
drug(s). 
I.4 Molecular simulations 
Simulation of the accessible surface area and free volume.  
The accessible surface area and free volume were calculated using a geometric computational 
approach. Two cases were considered with the accessibility of (i) both small and large spherical 
mesoporous cages and (ii) only the large cages, the accessibility of the small cages being 
prohibited by the presence of a dummy atom with a van der walls radius which fits with the 
diameter of the small cage.  
The theoretical accessible surface area of nanoMOFs powder was estimated using the method 
previously reported by Düren et al38. This surface was calculated from the center of a nitrogen 
probe molecule rolling across the surface. The diameters of each atom constituting the 
nanoMOFs were taken from the Universal Force Field (UFF)39 whereas the diameter of the 
nitrogen probe molecule was considered to be 3.60 Å.40 The calculations were performed using 
the crystal structure of MIL-100(Fe)41 with 2 iron centers per trimer unsaturated and the third 
one coordinated by an -OH group with a corresponding bond length of 0.97 Å. Two cases were 
considered with the accessibility of (i) both small and large spherical mesoporous cages and (ii) 
only the large cages, the accessibility of the small cages being prohibited by the presence of a 
dummy atom with a van der walls radius which fits with the diameter of the small cage. These 
predicted accessible surface areas were then compared with the BET experimental values 
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obtained before and after encapsulation of AMOX and CL. 
The free volume corresponding to the volume not occupied by the atoms of the MIL-100(Fe) 
nanoMOFs was also calculated using a similar method of trial insertions within the entire 
volume of the unit cell considering a probe size of 0 Å42. The experimental pore volume (0.66 
cm3/g) was lower than the theoretical free volume (0.99 cm3/g) calculated using a perfect and 
infinite crystal. Indeed, small sized nanoMOF crystals are far from being perfect and the void 
space of the nanoMOFs is only partially available for the drugs. Therefore, a scaling factor of 
1.5 was applied for the GCMC simulations, corresponding to the ratio (free 
volume/experimental pore volume). 
Structural features were calculated using Materials Studio software. The predictions of the 
optimal encapsulation uptake for AMOX and CL as single component and binary encapsulation 
in the MIL-100(Fe) were performed using Grand Canonical Monte Carlo (GCMC) simulations 
at 303 K. The MIL-100(Fe)/drugs and drugs/drugs interactions were treated as a sum of a 
Lennard-Jones (LJ) and a coulombic contribution. The microscopic models selected for both 
the drugs and the MIL-100(Fe), the associated LJ parameters and partial charges are described 
in SI section I.4.  Additional Monte Carlo simulations were conducted to reveal the preferential 
arrangements of both drugs in the pores of the MOFs. All the computational details are provided 
in SI section I.4.  
Prediction of AMOX and CL loadings and energetic considerations. The predictions of the 
optimal encapsulation uptake for AMOX/CL in the MIL-100(Fe) were performed using Grand 
Canonical Monte Carlo (GCMC) simulations at 303 K with the CADSS software (Complex 
Adsorption and Diffusion Simulation Suite)43. The crystal structure of MIL-100(Fe) was 
considered with one iron metal per trimer coordinated by an –OH group while the two other 
metal sites are coordinated by water molecules, to mimic the fact that encapsulation is achieved 
in aqueous media. The partial charges carried by each atom of the frameworks were extracted 
as a first approximation using the qEq charge equilibration approach44. This protocol has been 
revealed to be sufficiently accurate for screening the properties of a series of MOFs for carbon 
dioxide capture45. The partial charges of AMOX and CL were extracted by DFT calculations 
using the B3LYP functional associated with the 6/311++G (d,p) basis set46 as implemented in 
GAMESS47. The Lennard-Jones (LJ) parameters for all atoms of the MIL-100(Fe) frameworks 
and the drug molecules were taken from UFF4 and the general Amber Force Field (GAFF)48 
respectively. The MIL-100(Fe)/drugs and drugs/drugs were treated as a sum of a LJ and a 
coulombic contribution. The Lorentz-Berthelot mixing rule was employed for all cross LJ terms 
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and a cut-off radius of 14 Å was used. The long-range electrostatic interactions were handled 
by the Ewald summation technique. The GCMC simulations were performed for a series of 
fugacity for the drug up to 5000 kPa in order to first estimate the saturation capacity for each 
single drug. The simulations consisted of 106 steps to ensure the equilibration, followed by 2 × 
107 steps to calculate the ensemble averages. Additional GCMC calculations were performed 
to probe the co-encapsulation of the two drugs as well as their sequential uptakes. The predicted 
loadings were then converted into weight/weight encapsulation percentages for direct 
comparison with experimental DL values. The adsorption enthalpy for each drug was further 
calculated using the revised Widom’s test particle insertion method. 49 
Further, additional Monte Carlo simulations were performed with a crystal structure of MIL-
100(Fe) containing one iron metal per trimer coordinated by an –OH group while the two others 
are unsaturated to probe the preferential sitting sites of 1 molecule of AMOX and CL acid in 
the large and small cages respectively. 
I.5 NanoMOFs toxicity assays 
Cytotoxic effects of nanoMOFs were investigated using LDH assay. Following exposure to 
various concentrations of nanoMOFs as previously described, cells were washed and lysed. The 
activity of LDH was determined using a commercially available kit from Sigma. LDH reduces 
nicotinamide adenine dinucleotide (NAD), a coenzyme found in all living cells, to NADH, 
which is specifically detected by colorimetric (450 nm) assay. The absorbance was recorded 
using a microplate spectrophotometer reader system. 
I.6 Internalization of nanoMOFs  
Quantification of NanoMOFs internalized in the cells. J774 cells were seeded in 24-well-
plates (3×105 cells/wheel) and then incubated with nanoMOFs at a final concentration of 100 
µg/mL for 4 h in RPMI 1640 supplemented with 10% of FBS at 37°C, 5% CO2. They were 
washed thrice with cell culture medium, dried at 60°C for 2 h. Subsequently, 300 µL of 
hydrochloric acid (5M) was added and then incubated for 2 h at 60°C. Afterwards, 100 µL of 
each well were withdrawn and mixed with 100 µL of 4% potassium ferrocyanide in a 96-well-
plate and incubated at room temperature in the dark for 30 min. The absorbance was read at 
690 nm to quantify the amounts of internalized nanoMOFs. 
The absorbance was read at 690 nm to quatify the amounts of internalized nanoMOFs. 
NanoMOFs within cells were visualized by optical microscopy and TEM. Different 
pharmacological inhibitors (Cytochalasin D, Latrunculine, Wortmannin, Chlorpromazine, 
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Ikarugamycin, methyl-β-cyclodextrin) were used to investigate the nanoMOF cell 
internalisation mechanism (phagocytotic/endocytotic pathways). Practically, the cells were pre-
incubated 1 h with the above mentioned inhibitors before further incubation with nanoMOFs.  
Intracellular visualisation of nanoMOFs. NanoMOFs within cells were visualised by optical 
microscopy and TEM. Prussian blue staining (Sigma Iron staining kit) was applied for optical 
microscopy. After different incubation times with or without nanoMOFs, J774 cells were 
washed with complete medium and two times with PBS. Cells were fixed with 4% 
paraformaldehyde, washed and incubated for 10 minutes with 2% potassium ferrocyanide in 
0.6 mM hydrochloric acid. Cells were washed again, counterstained with pararosaniline 
hydrochloride (0.02%) and evaluated for iron staining using light microscopy.  
I.7 Intracellular antimicrobial activity of nanoMOFs. 
Intracellular antimicrobial activity of nanoMOFs. The antimicrobial activity of nanoMOFs was 
investigated against S. aureus ATCC55585 and against a clinical penicillin-resistant S. aureus. 
It was carried out in a quantitative assay based on dilution method, using the Mueller-Hinton 
medium and the Minimum Inhibitory Concentration (MIC) was determined. Briefly, 2.5×105 
J774 cells were seeded in 24 well plates and incubated overnight (37°C, 5% CO2). The cells 
were washed with cell culture medium (RPMI 1640 containing 10% v/v decomplemented FBS) 
and then incubated for 2 h with or without different amounts of nanoMOFs, loaded or not with 
drugs. The cells were washed twice with complete cell culture media, to eliminate extracellular 
nanoMOFs and drugs. Then, they were infected with 500 µl of S. aureus suspension 
(ATCC55585) at 5×106 bacteria/mL (multiplicity of infection, MOI=10) and incubated for 2h. 
After washing the cells, gentamicin was added to kill extracellular bacteria. The ROS effect 
was inhibited at this moment with Tiron 10 mM. After 1, 6 and 24 h of incubation, cells were 
washed again with cell culture media and lysed by treatment with ice-cold water during 1 h. 
The lysates were plated at serial dilutions in sterile phosphate buffered saline (PBS, pH=7.4) 
on agar plates. The plates were incubated at 37°C overnight and the number of formed colonies 
(CFU) was evaluated50. 
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 I.1 X-ray powder diffraction (XRPD) characterization 
XRPD experiments were performed to investigate the effect of drug loading and nanoMOF 
incubation in various media on their crystalline structures. 
 
Fig. S1. X-ray powder diffraction (XRPD) patterns of empty and drug loaded nanoMOFs. 
Drug entrapment didn’t modify the XRPD patterns of nanoMOFs (Brown: empty nanoMOFs 
in ethanol; Dark blue: empty nanoMOFs in water; Dark red: nanoMOFs loaded with 13 wt% 
AMOX and 22 wt% CL). Degradation was only observed when the nanoMOFs, loaded (purple) 
or not (orange) with drugs, were incubated in the cell culture media (RPMI, 2 h, 37 °C).   
As shown in Fig. S1, the XRPD patterns of the drug loaded MOFs were very similar to the ones 
of empty nanoMOFs, suggesting that the incorporation of AMOX and CL didn’t affect the 
crystallinity of the nanoMOFs. However, the incubation of nanoMOFs, containing or not drugs, 
in cell culture medium (RPMI) for 2 h lead to a diminution of the intensity of the peaks in the 
region 3°- 4°, showing nanoMOF degradation.   
I.2 Effect of different pharmaceutical inhibitors on the internalisation of nanoMOFs in 
J774 cells 
The cell viabilities were higher than 90% when the nanoMOFs concentration was lower than 
50 μg/mL. A concentration of 12.5 μg/mL was chosen for the cell internalization studies.  
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Cytochalasin D, Latrunculine A Wortmannin, Chlorpromazine, Ikarugamycin, methyl-β-
cyclodextrin (Mβ-CD), Genistein, and Fillipin III were used as pharmacological inhibitors to 
investigate the mechanisms of internalisation of nanoMOFs inside J774 cells. The inhibitors 
were incubated with the cells for 1 h, previously to adding the nanoMOF suspensions. Results 
are gathered in Fig. S2. 
The internalization of nanoMOFs was reduced by 35% in the presence of Cytochalasin D1 and 
Latrunculin A2, which block actin polymerization and hence disrupt microfilament-mediated 
internalization, manifesting the role of phagocytosis. Wortmannin1, Ikarugamycin3, and 
Chlorpromazine4, used as inhibitors of clathrin-dependent endocytosis, didn’t significantly 
lessen the uptake of nanoMOFs, indicating that clathrin-pathway hardly played a part in the 
internalization. Genistein4 and Filipin III5, which block caveolin-mediated endocytosis, didn’t 
significantly affect the internalisation. Mβ-CD, used in previous studies4 to induce cholesterol 
depletion of cellular membrane, had no influence on the nanoMOF internalisation, neither. 
Furthermore, it was found that the nanoMOF incubation temperature plays a major role. The 
uptake of nanoMOFs was reduced by 60% when the temperature was decreased to 4oC, 
suggesting an energy-dependent internalization mechanism. As a conclusion, nanoMOFs were 
mainly internalised in J774 macrophages by phagocytosis. 
  
  
Fig. S2. Effect of different pharmaceutical inhibitors on the internalisation of nanoMOFs 
in J774 macrophages. The cells were pre-incubated for 1 h at 37°C with different inhibitors 
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(B: Cytochalasin D; C: Latrunculine A; D: Wortmannin; E: Chlorpromazine; F: Ikarugamycin; 
G: methyl-β-cyclodextrin; H: Genistein; I: Fillipin III) before further incubation with 
nanoMOFs. A: the cells were incubated with the nanoMOFs at 4°C instead of 37°C. All data 
are normalized as compared to the uptake of nanoMOFs at 37°C in the absence of any inhibitor. 
I.3 Bactericidal effect of empty nanoMOFs 
Interestingly, cell internalized empty nanoMOFs exhibited a bactericidal effect which was 
proportional both to the amount of nanoMOFs initially in contact with the cells and the 
incubation time (Fig.S4). A significant bactericidal effect of empty nanoMOFs was observed 
when the amount of nanoMOFs initially in contact with the cells was higher than 12.5 μg/mL 
and after 6 h of incubation. 
 
Fig. S3. Effect of nanoMOFs concentration on their bactericidal effect. (light blue: 1 h after 
infection; dark blue: 6 h after infection). There is a significant difference when the concentration 
of nanoMOFs is higher than 12.5 μg/mL (P< 0.05, *). 
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General Discussion and Perspectives 
Although people have already been using medicinal substances as far as there have been people, 
the history of pharmacy as an independent science dates back to the 19th century when chemical 
companies established their research labs for medical applications of their products. The last 
two centuries witnessed the outstanding progress of pharmaceutical science. In 1970s, 
microparticles (MPs) and NPs were applied as drug carriers, which are recognized as the first 
pioneering works for the further development of functionalized formulations. Recently, 
formulations for targeting 1 and personalized treatment 2 are attracting increasing attentions 
aiming to deliver the drug directly to the diseased cells and tissues of the body, and therefore 
enhance the drug’s efficacies, decrease the treatment’s side effects, and improve the patient’s 
life quality. 
The use of nanotechnologies for the treatment of diseases has led to new therapeutic strategies. 
Many functionalized NPs developed in the lab allow the efficient targeting, as well as the 
controlled drug release in these specific biological targets. However, the journey of a 
nanomedicine from lab to shelf is quite costly and time consuming 3. Statistically, the research 
and development of a new drug to the market takes around 12 years and costs around £1.15 
billion, while tens of thousands of candidate drugs fail. One of the main reasons that limits drug 
commercialization is the fact that their preparation needs to employ large amounts of potentially 
toxic organic solvents and surfactants, which is often not acceptable, at least for parenteral 
administration. For instance, a variety of polymer NPs were prepared by the well-known solvent 
evaporation method using volatile organic solvents to solubilize the polymer. Traces of solvents 
are very difficult to remove even using very complicated and time consuming methods such as 
ultradialysis, ultrafiltration or ultracentrifugation. 
Therefore, there is an urgent need to develop particle preparation procedures avoiding the use 
of organic solvents and surfactants. Herein, CD-based NPs were prepared in pure water just by 
mixing two neutral polymers which instantaneously associate together by a “lock and key” 
mechanism (Chapter 2). In this chapter, we show not only the concept that host–guest 
interactions between hydrophobic molecules (Bz moieties) and the apolar cavities of CDs can 
be exploited for the formation of stable NPs, but also that this preparation can be successfully 
scaled up by microfluidics, an automatic technique. Briefly, two polymers for NPs preparation 
were firstly synthesized: i) a poly-CD polymer and ii) Dex-Bz polymer where Bz moieties were 
grafted with dextran. Bz acts as both the hydrophobic moiety that interacted with CDs and also 
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the active ingredient. By mixing the aqueous solutions of these two polymers with 
microfluidics, CD-NPs of around 100 nm were spontaneously formed with narrow size 
distribution. Although CD-NPs could also be prepared manually with pipette, it is very difficult 
to well control the procedure for NPs preparation, whereas the microfluidic chamber allows for 
exquisite control over the mixing profile of the solutions containing the NPs forming agents4,5. 
Parameters, including ratio between the different compounds, flow rate as well as temperature 
can be easily and accurately controlled, which make possible to prepare NPs in a well-
controlled, reproducible and high-throughput manner. Moreover, the microfluidic device could 
allow a continuous NP production at a rate of tens to hundreds of microliters per minute. Studies 
in the literature 6 describe the utility of microfluidic devices to scale up the NP production. 
The other novelty in this study is the use of NTA to evaluate the NPs’ stability in terms of size 
distribution and concentration upon extremely dilution. As the inclusion complexes were 
formed by host-guest interaction, instead of covalent bonds, an equilibrium exists all the time 
between the components in the system, as described in introduction (section 1.3). When the 
system is extremely diluted, the equilibrium will shift to the disassociation of the inclusion 
complexes, which would induce the disassembly of the CD-NPs. NTA allows to measure the 
size distribution and concentration at extremely diluted condition by individually following the 
CD-NPs in their Brownian motions. Remarkably, CD-NPs were very stable even when their 
concentration was as low as 100 ng/mL.     
The solvent-free “green” procedure and the remarkable stability of CD-NPs make them 
promising as drug carrier for hydrophobic drugs which fits with the cavity of CDs. However, 
considering the payload of active ingredient, which is normally less than 5 wt%, their 
application for many drugs is limited, especially when large doses are needed for the diseases, 
as it is the case with antibiotics. But they are still good candidates for drugs with small dosages 
such as anticancer drugs. 
To improve the drug payload, the next strategy that we explored is to use “cage” porous 
particles. CD-MOFs were the first particles tried in this study since it is built with the “cage” 
molecules (CDs). The use of CD-MOF materials for biomedical applications requires them to 
have very homogeneous sizes. Before their applications as drug carriers, the optimization of the 
synthesis and the evaluation of their crystalline structure were performed. (Chapter 3.1). In this 
subchapter, a fast solvent evaporation approach was developed to synthesize and tailor the CD-
MOFs to a controlled size, with the synthesis time shortened from the reported 26 h 7 to only 6 
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h. The size of CD-MOFs were well controlled by adjusting the reactant concentrations and 
molar ratios, temperature and reaction time, without any significant changes in crystallinity and 
porosity. A modified hydrothermal protocol has been established which produces efficiently at 
50 °C in 6 h micron (5–10 µm) and nanometer (500–700 nm) diameter CD-MOF particles of 
uniform size with smooth surfaces and powder X-ray diffraction patterns that are identical with 
those reported in the literature 7. 
CD-MOFs experienced degradation at high temperature (100 °C), high humidity (92.5%) and 
with polar solvents (methanol and DMF). More importantly, it was found that γ-CD was 
released and characteristic peaks in PXRD patterns disappeared when immersing the CD-MOFs 
in polar solvent whilst the morphology remained unchanged. After the stability study, the 
preliminary experiments on drug adsorption were performed with more than 20 drugs, the 
results shows that CAP has high affinity with CD-MOFs reaching payloads as high as 19.3 
wt%, which corresponding to a molar ratio between CAP and γ-CD close to 1.6:1. These results 
confirm the high drug loading capacity of CD-MOFs. 
LPZ was then used as drug of especial interest, as it is a proton-pump inhibitor used to reduce 
the production of acid in the stomach and recently identified as an antitubercular prodrug 8. CD-
MOFs of around 6 µm in diameter were used for LPZ encapsulation. LPZ-loaded CD-MOFs 
were successfully synthesized by a co-crystallization method, obtaining cubic crystals with the 
uniform size of around 6 µm. High drug payloads of 23.2 wt% were obtained, and calculations 
indicated that each CD in the CD-MOFs was able to host one LPZ molecule. Moreover, it was 
demonstrated that even after two years storage, the incorporated drug inside the CD-MOFs 
maintained its spectroscopic characteristics. Compared to other CD-based drug carriers, CD-
MOF appears as one of the best systems in term of drug payload. 
The CD-MOFs loaded or not with LPZ were fully characterized to gain a deep insight of the 
system. XRPD patterns of LPZ loaded CD-MOFs show that the peaks corresponding to the 
LPZ were not observed, indicating that LPZ was incorporated in CD-MOFs in amorphous state. 
As a crystalline drug, incorporation of LPZ is very challenging since the drug might form 
crystals which are not well encapsulated and difficult to be separated from the drug-loaded 
particles, hampering the medical applications. However, we demonstrated that in CD-MOF 
crystals, all the LPZ molecules located in each cavity of CDs, which possibly prevented the 
LPZ crystallization. Molecular modelling gave deeper insight into the interactions between LPZ 
and CD-MOFs showing that LPZ molecules preferred to insert in the γ-CD cavities of the CD-
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MOFs instead of locating in the hydrophilic large pores. LPZ molecules were bended 
interacting strongly with the CD cavities mainly through their benzo imidazole and pyridine 
moieties. This result surprisingly indicated that the inclusion complexes formed between LPZ 
and CDs could self-assemble with coordinated K+ ions into the cubic CD-MOF crystals. 
Furthermore, we set up a novel characterization method based on Raman microscopy allowing 
to gain information on the structure and chemical composition of individual particles. 
Thistechnique combines the advantages of Raman spectroscopy and optical microscopy. 
Individual CD-MOF crystals could be analyzed in terms of morphology (particle size, shape) 
and chemical composition, enabling to confirm the homogeneity of the CD-MOF population. 
Morphologies of more than 2500 particles were analyzed, showing almost perfect cubes with 
diameters around 6 µm, before or after drug loading. Raman investigations confirmed the 
effective LPZ incorporation in CD-MOFs and suggested an interaction between γ-CD and LPZ, 
more specifically between the CDs and the benzo imidazole and pyridine moieties of LPZ, 
which agrees with the theoretical molecular modelling results. Of note, it was found that Raman 
spectra of different individual particles were the same, showing a remarkable homogeneity in 
terms of drug loading. 
These results pave the way towards the use of CD-MOFs for drug delivery purposes, especially 
for pulmonary administration. Considering the size of CD-MOFs and the antitubercular effect 
of LPZ, the LPZ loaded CD-MOF crystals are quite promising as inhalation for tuberculosis, 
an infectious disease that occurs the lungs. Compared with other diseases caused by a single 
infectious agent, tuberculosis is the second biggest killer, globally. Pulmonary administration 
has recently gain more attention as it enables to deliver the drugs directly to lung both for local 
and systemic treatment 9. For further study, the interactions between pulmonary surfactant and 
CD-MOFs would be interesting to investigate. Afterwards, in vitro evaluation of the drug 
loaded particles to kill tuberculosis could be performed in macrophage. 
For other routes of administration except pulmonary inhalation, the drawback of CD-MOFs lies 
on the fact that they disassemble immediately in water, leading to burst release before the 
particles reach the target tissues or organs. In order to enlarge the scope of their application for 
more routes of administration, surface modification was designed to prepare CD-MOF/polymer 
composites, which are emerging as a new class of carriers for sustained drug delivery. In the 
literature, most of the MOFs and the polymers used so far in these composites are not 
pharmaceutically acceptable. Herein, biocompatible CD-MOFs were embedded inside 
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polyacrylic acid (PAA) polymer matrices by a solid in oil-in-oil emulsifying solvent 
evaporation method. Since the size of the solid dispersed in the internal phase needs to be as 
small as possible, hence, nanometer-sized CD-MOFs (around 650 nm in diameter) were 
selected in order to prepare CD-MOFs/PAA composite microspheres. Ibuprofen (IBU) and 
LPZ, both insoluble in water and lacking in stability, were entrapped with high drug loading in 
nano-scaled CD-MOFs by co-crystallization without causing MOF crystal degradation during 
the loading process. Nano-scaled CD-MOF crystals dispersed well inside PAA matrices leading 
to their uniform distribution in the microspheres, which further allowed the obtention of 
composite microspheres with spherical shapes. On the contrary, microspheres prepared with 
drug-γ-CD complexes have non spherical shapes since the size of the drug-γ-CD complexes 
was larger and not uniform when compared with the drug-loaded CD-MOF nanocrystals, even 
after sieving. Particle aggregation occurred during microsphere preparation with drug-γ-CD 
complexes. 
Burst release is considered to be one of the main drawbacks hampering the NP applications. 
Achieving sustained drug release is important for drug formulations. In vitro cumulative drug 
release profiles showed sustained drug release from CD-MOF/PAA microspheres. IBU was 
released slowly over 48 h, whereas LPZ enabled a sustained release also during 48 h with an 
almost linear profile. However, microspheres containing IBU-γ-CD and LPZ-γ-CD complexes 
both showed a very fast burst and uncontrolled release – i.e., 70% in 30 min for IBU and 80% 
in 2 h LPZ. With no doubt, this observation reflected the good dispersion of drug-loaded CD-
MOF nanocrystals in the microspheres and the homogeneous distribution of the drug molecules 
within these crystals, resulting from the efficient co-crystallization loading process. 
Cytotoxicity is one of the most crucial parameters to evaluate the drug carrier. The cellular 
toxicity study showed that CD-MOFs were not toxic (cell viability > 90%) even at 
concentrations as high as 300 µg∙mL-1. At concentrations up to 1.4 mg∙mL-1, the cellular 
viability was still high (~ 80%). Interestingly, the toxicity of IBU loaded CD-MOF/PAA 
composite microspheres was reduced dramatically. The cell viability was around 90% even for 
samples at high concentrations of 17.5 mg∙mL-1, corresponding to a CD-MOF nanocrystal 
concentration of 1.4 mg∙mL-1 and IBU concentration of 0.2 mg∙mL-1. These results showed that 
composite of CD-MOF nanocrystals in PAA microspheres could to be used as safe carriers for 
sustained drug delivery. 
Taking into account the bio-adhesive properties of PAA and its excellent biocompatibility, the 
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composite microspheres have potential applications for biomedical applications and, in 
particular, for oral drug delivery. However, a limitation of the CD-MOF/PAA microspheres is 
that their drug loading is relatively low (about 1%, w/w) and so this system would be better 
adapted for the delivery of drugs requiring lower doses, such as anti-tumor drugs. 
While CD-MOFs seem very promising for pulmonary administration, their applications for 
other routes of administration are limited by their physical frailness and their high solubility in 
aqueous media before surface modification or the low drug payloads after modification.In this 
context, our alternative strategy was to use stable porous particles to obtain both high payloads 
and high stability in water. However, although stability is very important, drug carriers need to 
be degraded inside the body for excretion. MIL-100 (Fe) MOFs are stable in water and could 
be degraded in a series of simulated physiological fluids. They are also considered among the 
most efficient materials for biomedical applications because of their unprecedented drug 
loading capability and biocompatibility 10. In this view, MIL-100 (Fe) was chosen as the third 
drug delivery system. 
Firstly, the degradation mechanism of MIL-100 (Fe) was investigated. As reported, MIL-100 
(Fe) interacted efficiently with phosphate groups. Phosphated drugs, such as Gem-MP, were 
soaked from their aqueous solutions with high payloads (> 25wt%) and efficiencies (> 98%), 
and phosphated coatings, such as CD-P, were attached to the outer surfaces by incubation just 
in water. Unfortunately, MIL-100 (Fe) readily degraded in phosphate buffers leading 
sometimes to uncontrolled drug release. It is therefore necessary to have a deep understanding 
of the MIL-100 (Fe) degradation mechanism in complex media containing phosphates to be 
able to control it.  
To better understand their degradation mechanism in PBS and the complex interactions taking 
place in the MOF/drug/coating systems, we developed a method based on Raman microscopy 
to track the morphology and chemical composition of individual particles. It was shown that 
MIL-100 (Fe) MOFs degraded in PBS releasing their constitutive trimesate linkers and leading 
to the formation of amorphous material, whereas the particle sizes remained unchanged. It was 
extremely interesting and fascinating to observe that despite the fact that more than 80% of the 
connective linkers were released, the particles perfectly maintained their initial morphology. 
Remarkably, Raman spectra of different regions on the same particle could be recorded, 
evidencing the formation of an erosion front during MOF degradation. This front clearly 
separated an intact non eroded crystalline core from an amorphous shell made essentially of an 
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inorganic network. To gain a deeper understanding of the kinetics of the degradation process 
of single particles, automated imaging was used track the degradation process by capturing 
MOFs’ images every half an hour during 8 days degradation. 
Of interest, the method provided a direct measurement of the size, shape, color, surface area, 
and circularity of each particle. A fast degradation phase was observed in the first 6 hours with 
a rapid color change and increase of surface areas, which were too subtle to be observed by the 
naked eye. A second phase occurred in the following 8 days with the formation of an eroded 
zone with a clear color change (progressive phase). It can be speculated that in the first hours 
after incubation, a fast coordination reaction occurred between phosphates in the incubation 
medium and accessible iron sites at the MOF surface. This phase was followed by a slower 
diffusion of phosphates in the eroded region. The advancement of the degradation front was 
presumably limited by the diffusion of the reacting species (phosphates) from the media into 
the MOFs and by the diffusion of released trimesate out of the matrix. 
To investigate the chemical composition of the eroded zone, 57Fe Mössbauer spectrometry was 
applied to MIL-100 (Fe) particles before and after degradation. Before degradation, the 
spectrum was well described by means of 3 quadrupolar components, in agreement with the 
crystallographic MIL-100 (Fe) structure, while after degradation, quadrupolar doublets with 
broadened lines were observed. The best physical description requires a discrete distribution of 
quadrupolar doublets suggesting a structure close to that of a typical amorphous structure. 
Although the hyperfine structures of the nano-and microMOF samples after degradation was 
modified, the refined values of the isomer shift indicate unambiguously the presence of only 
Fe3+ species whatever the sample (nano-and microMOFs) and their degradation state. It could 
be concluded that no Fe reduction occurred during degradation. Taking into account the 
presence of phosphates in the media surrounding the MOF, it is plausible that a highly 
disordered Fe-P based skeleton phase was formed.  
In contrast, neither drug entrapment nor particle coating did affected the integrity of the 
tridimensional MOF network. As descripted, MOFs degraded in PBS with kinetics dependent 
upon the amount of phosphates in the suspension media. When Gem-MP was loaded in MOFs, 
the equivalent amount of phosphates was up to 100 times lower than that in diluted PBS (1.19 
mM), which could explain the reason why MOFs did not degrade during drug entrapment. 
When MOF particles were coated with CD-P, which could not penetrate inside the 
tridimensional MOF network, no degradation was induced. The good stability of the particles 
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after Gem-MP loading and CD-P coating offer promising possibilities to load drugs of interest 
and graft ligands for targeting purposes. These findings are of interest in the development of 
stable drug-loaded iron trimesate particles. 
Combinatorial drug therapies are considered among the most effective strategies for the 
treatment of complex pathologies such as cancer and severe viral or bacterial infections 
involving multiple molecular and genomic pathways. However, co-administration of synergic 
drugs is challenging because of the differences in pharmacokinetics and biodistribution of each 
individual drug. Nanotechnology revolutionizes drug delivery in many aspects, but there are 
still few examples of NPs for drug co-encapsulation, such as Janus NPs, nanocapsules and 
polymersomes which are composed of several macroscopic compartments, each one being 
adapted to accommodate a specific drug. However, the preparation of anisotropic NPs are 
relatively complex and require the use of organic solvents and surfactants. 
Taking advantage of the two types of “cages” present in MIL-100 (Fe) nanoMOFs, synergic 
antibiotics AMOX and CL were co-entrapped inside the porous “cage” nanoMOFs. AMOX 
and CL are typical drugs used in tandem to treat a variety of bacterial infections, mainly 
rhinosinusitis, ear infections, pharyngolaryngitis, tonsillitis, bronchitis and urinary tract 
infections. By using a simple “green” strategy consisting of incubating the nanoMOFs with 
aqueous solutions of both drugs, AMOX and CL were easily co-encapsulated. As a general 
trend, when drugs are co-encapsulated, one drug in the combination reduces the entrapment of 
another. Interestingly, the AMOX and CL were co-incorporated inside nanoMOFs without 
impeding each other. The combinational payload reached at maximum 35 wt%, including 22 
wt% of CL and 13 wt% of AMOX. Molecular modelling gave a clear picture of location for the 
two drugs, showing that AMOX occupied mainly the large cages and CL the small cages. 
Considering their excellent drug encapsulation properties, nanoMOFs were further studied in 
vitro on S. aureus infected cells. NanoMOFs were able to penetrate inside infected 
macrophages, whereas free drugs could poorly bypass cell membranes and/or are rapidly 
cleared off mainly because of efflux pumps. NanoMOFs, loaded or not with drugs, were non-
toxic tested by MTT assays. Surprisingly, empty nanoMOFs co-localized with bacteria in 
macrophages and had bactericidal effect, proportional to the amount of nanoMOFs initially in 
contact with the cells. AMOX-loaded nanoMOFs were successful to show synergic effect with 
empty nanoMOFs, whereas no bactericidal effect was found with free AMOX, which is 
reasonable due to its poor intracellular penetration. When using a resistant S. aureus strain, the 
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bactericidal effect due to internalized nanoMOFs was so strong (85% bacteria were destroyed), 
that it was comparable to that of (co)encapsulated drugs. (Need to be adapted according to the 
ongoing study). In conclusion, intracellular nanoMOFs synergistically contribute with 
encapsulated drugs to eradicate intracellular bacteria. They are efficiently taken up inside 
macrophages essentially by phagocytosis and advantageously co-localize with bacteria, to 
eventually deliver their drug cargo. These results pave the way towards the design of engineered 
nanocarriers in which each component synergistically plays a role in fighting the disease. 
For future study, it would be very interesting to deeply investigate the mechanism of 
antimicrobial effect of empty MIL-100 (Fe) nanoMOFs. The growing resistance of pathogens 
has become a public health problem. New effective antimicrobial materials are necessary and 
urgent for resistant pathogen treatment. It was discovered that nanoMOFs, entirely different to 
antibiotics, played a role as antibacterial materials providing promising novel solution to the 
problem of drug resistance. There are already some reports on antimicrobial MOFs based on 
Cu, Co, Zn, and Ag, but no reports on MOF based on Fe yet, to the best of our knowledge. 
Understanding their bactericidal mechanisms could help not only to explain the obtained 
results, but would be also beneficial to design new antimicrobial materials.  
The current antibacterial mechanisms of reported MOFs involves 11: 1) release of metal ions, 
such as Ag+ 12; 2) reactive oxygen species (ROS) formed by metal oxides, especially ZnO, NiO, 
CoO, CuO, and Cu2O 
13; 3) antibacterial autophagy 14. It would be very interesting to understand 
the main antibacterial mechanisms for MIL-100 (Fe) nanoMOFs. 
MOFs are an emerging class of materials suitable for infection treatment by encapsulation of 
antibiotics and their intrinsic antimicrobial properties. The two types of MOFs used in this study 
were able to efficiently load large amount of drugs for infection treatments. LPZ loaded CD-
MOFs are very promising particles as pulmonary inhalation for tuberculosis treatment, whereas 
AMOX and CL loaded nanoMOFs could be used for many infections using different routes of 
administration.  
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General Conclusion 
In this study, three different types of “cage” particles were prepared in view of possible 
biomedical application. 
1.  CD-NPs of around 100 nm were prepared by a “green” and simple preparation procedure 
consisting in mixing poly-CD aqueous solution and Dex-Bz aqueous solution using 
microfluidics or just pipettes. The host–guest interactions between β-CD in poly-CD 
polymer and Bz in Dex-Bz contributed to the spontaneous formation of stable CD-NPs. 
CD-NPs were instantaneously produced by mixing 2 aqueous solutions of neutral 
polymers. Despite their non-covalent nature, the CD-NPs were extraordinarily stable in 
terms of concentration and size distribution, even on extreme dilution (concentrations 
as low as 100 ng/mL). 
2. In order to improve the drug loading in CD-based drug delivery systems, uniform cubic 
CD-MOFs were successfully synthesized. An optimized vapor diffusion method was 
developed at elevated temperature (50 °C) within 6 h, which is much shorter than the 
reported time (>24 h). Both microcrystals (~ 6 µm) and nanocrystals (~ 650 nm) were 
obtained by adjusting the amount of the pre-added methanol to the aqueous solution of 
γ-CD and KOH. 
3.   LPZ is a proton-pump inhibitor used to reduce the production of acid in the stomach and 
recently identified as an antitubercular prodrug. It was encapsulated in CD-MOF 
microcrystals (~ 6 µm) with payload up to 23.2 ±2.1% (wt) by co-crystallization 
method, where the drug was added during particle synthesis. The crystalline particles, 
loaded or not with LPZ, have almost perfect cubic morphologies with monodispersed 
size distributions. The interactions between LPZ and CD-MOF were revealed by 
molecular modelling. The formation of inclusion complexes within the tridimensional 
CD-MOF structures was confirmed by Raman spectra of individual particles, which also 
demonstrated that each individual particle had identical chemical composition, 
indicating a remarkable homogeneity in terms of drug loading. Moreover, the 
incorporated LPZ inside the CD-MOFs maintained its spectroscopic characteristics 
even after two years storage. 
4.  The drug loaded CD-MOF nanocrystals (~ 650 nm) were successfully embedded in 
polyacrylic acid (PAA) polymer matrices by a solid in oil-in-oil emulsifying solvent 
evaporation method. The composite microspheres exhibited spherical shapes and 
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sustained drug release over a prolonged period of time (over 48 h). No burst release of 
IBU (and LPZ) was observed from the CD-MOF/PAA composite microspheres, 
suggesting the homogeneous distribution of CD-MOF nanocrystals inside PAA 
matrices as well as strong drug carrier interactions inside the CD-MOF. Sustained 
release was achieved for IBU (and LPZ)-CD-MOF/PAA composite microspheres (ca. 
50% in 24 h). The cellular toxicity study shows that IBU loaded MOF/PAA composite 
microspheres are not toxic (cell viability ~ 90%) even at very high concentrations of 
17.5 mg∙mL-1. In conclusion, MOF/PAA composite microspheres constitute an efficient 
and pharmaceutically acceptable MOF-based carrier for sustained drug release.   
5.  Biodegradable iron trimesate MOFs, MIL-100 (Fe), degraded in PBS losing their 
crystallinity and constitutive trimesate linkers, whereas, they kept their morphology 
intact. The degradation mechanism was revealed by Raman microscopy via recording 
spectra in different regions on the same particle, showing that intact cores were 
separated from the eroded regions by clearly visible erosion fronts. Mössbauer 
spectroscopy supported the hypothesis that Iron phosphates were formed in the eroded 
regions. In contrast, the integrity of the tridimensional MOF network was not affected 
by drug entrapment nor by particle coating. 
6.   Co-encapsulation of two synergic antibiotics (AMOX and CL) in MIL-100 (Fe) 
nanoMOFs was achieved following a simple and “green” procedure consisting of 
incubating the nanoMOFs with aqueous solutions of both drugs. Molecular modelling 
showed that each drug preferentially located in a separate compartment (large or small 
mesoporous cage) of nanoMOFs. Surprisingly, nanoMOFs were prone to co-localize 
with bacteria once internalized in infected macrophages. NanoMOFs acted 
synergistically with the entrapped drugs to kill intracellular S. aureus, in vitro. These 
results pave the way towards the design of engineered nanocarriers in which each 
component synergistically plays a role in fighting the disease. 
These studies unravel the potential of “cage” nanoparticles for efficient drug entrapment and 
release. They open new routes of investigation especially in the field of the treatment of severe 
intracellular infections. Moreover, it was shown that “cage” particles are not just simple 
“carriers” but could play a role in killing bacteria. 
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Conclusion Générale 
Les systèmes à délivrance de médicaments sont des technologies conçues pour administrer des 
molécules actives de façon optimisée afin d’améliorer leurs effets thérapeutiques tout en 
minimisant les effets secondaires. En effet, ces systèmes permettent une libération au niveau 
d’une cible thérapeutique. Les particules de type "cage" ont récemment attiré une attention 
particulière en raison de leur capacité accrue à (co)incorporer et à protéger des molécules 
actives vis-à-vis de dégradations in vivo.  
Les cyclodextrines (CDs) sont des exemples type de molécules "cage", possédant une cavité 
hydrophobe et une surface extérieure hydrophile. Nous avons élaboré tout d’abord des 
assembages supramoléculaires à base de CDs d'environ 100 nm par une méthode douce 
consistant à mélanger deux solutions aqueuses de polymères neutres: 1) polymère de β-CD et 
2) dextrane greffé avec la benzophénone (Bz), molécule invitée formant des complexes 
d’inclusion avec les CDs. La procédure de préparation "verte" en une seule étape rend la 
formulation attractive, malgré sa relativement faible capacité d’encapsulation (5% pds). Afin 
d'améliorer cete charge, nous avons élaboré des particules hybrides organiques-inorganiques 
(MOFs) à base de CDs (CD-MOFs). Avantageusement, les CD-MOF comportent non 
seulement des cavités de CD, mais aussi de larges pores engendrés lors l’auto-assemblage de 
CDs. Le lansoprazole (LPZ) a été incorporé avec sucès (23% pds) dans les CD-MOFs et nous 
avons montré que chaque CDs était capable d’accueillir une molécule de principe actif. 
Cependant, l’inconvénient majeur des CD-MOFs est leur faible stabilité en milieu aqueux, 
limitant leur domaine d’aplication. 
Une modification de surface est apparue donc nécessaire pour améliorer leur stabilité. Notre 
statégie a été d’incorporer les CD-MOFs dans des matrices d'acide polyacrylique (PAA). Des  
microsphères composites d’environ 650 nm ont été élaborées avec succès et ont permis une 
bone stabilité et une libération prolongée sur plus de 48 h. Avantageusement, ces particules 
composites n’étaient pas toxiques in vitro même à des concentrations élevées. 
Ces microsphères apparaissent comme des systèmes efficaces pour assurer une bonne stabilité 
dans de milieux biologiques et une libération prolongée, mais leur synthèse est laborieuse et 
leur taille ne peut pas être réduite en dessus de 50 nm. 
Ainsi, nous nous sommes orientés vers l’étude comparative de MOFs plus stables dans l’eau, à 
base de trimesate de fer. Les MIL-100 (Fe) (MIL signifie Matériel of Institute Lavoisier) 
figurent parmi les premiers MOF étudiés en tant que nanomédicaments (nanoMOFs). Ces 
194 
 
particules, parfaitement stables dans l'eau, se dégradent dans des milieux contenant des 
phosphates (PBS) en perdant rapidement leur caractère cristallin et leurs ligands constitutifs. 
De façon étonnante, nous avons constaté que malgré leur dégradation, ces MOFs conservent 
leur taille intacte. Une analyse approfondie basée sur la microscopie de Raman a permis 
d’obtenir des informations pertinentes sur la morphologie et la composition chimique de 
particules individuelles. Ainsi, il a été montré qu’un front d'érosion délimitait nettement un 
cœur intact et une coquillé inorganique érodée. Cependant, ni l’encapsulation ni la modification 
de surface des MOFs n’altérait leur intégrité. Enfin, nous avons étudié la co-encapsulation de 
deux molécules actives utilisées en combinaison (Amoxicilline et Clavulanate de potassium) 
dans les nanoMOFs stables à base de MIL-100 (Fe). Les antibiotiques ont été incorporés par 
imprégnation et chaque molécule s’est localisée préférentiellement dans un compartiment 
(large ou petite cage) corroborant parfaitement les simulations par modélisation moléculaire. 
De plus, il a été découvert, de manière surprenante, qu’un grand nombre de nanoMOFs se 
localisait au voisinage des bactéries (Staphylococcus aureus) dans des cellules infectées. En se 
dégradant dans ces cellules, les nanoMOFs contenant les antibiotiques ont réduit de manière 
importante la charge bactérienne intracellulaire. 
Ces études révèlent le potentiel des particules de type "cage" pour une incorporation efficace 
de molécules actives et leur libération contrôlée et ouvrent de nombreuses possibilités 
d’application.  
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Annex I: Evaluation of drug loading capabilities of γ-cyclodextrin-metal 
organic frameworks by high performance liquid chromatography
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Annex II: Improvement in thermal stability of sucralose by 
γ-cyclodextrin metal-organic frameworks 
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Abstract : Drug delivery systems are 
engineered technologies to administer  
pharmaceutical ingredients to improve their 
therapeutic effects, aiming at minimizing their 
side effects by means of targeted delivery and/or 
controlled release. “Cage” particles recently 
drew special attention since they could act as 
“drug containers” which potentially load large 
amount of drugs, improve their stability and 
offer the possibilities to co-encapsulate 
synergetic drugs.  
Cyclodextrins (CDs) are typical “cage” 
molecules with a hydrophobic cavity and a 
hydrophilic outer surface. Taking advantage of 
the host-guest interactions between β-CD and 
benzophenone (Bz), CD based nanoparticles 
(CD-NPs) were the first formulation 
investigated.  CD-NPs of around 100 nm were 
instantaneously produced by mixing two 
aqueous solutions of neutral polymers : 1) poly-
CD containing β-CDs, and 2) Bz grafted Dex 
(Dex-Bz). The “green” and facile preparation 
procedure makes it attractive formulation, 
whereas its limitation lies on the low drug 
payloads (~ 5 wt%). 
In order to improve the drug loading capacity of 
CDs, porous CD based metal orgainc 
frameworks (CD-MOFs) were synthesiezed, 
which contain not only CD cavities, but also 
large pores built up by CDs self-assembly. 
Lansoprazole (LPZ)  was incorporated in CD-
MOF microcrystals (~ 6 µm) reaching payloads 
as high as 23.2 ± 2.1% (wt). Remarkably, each 
CD cavity was able to host a drug molecule, 
offering new opportunities for the use of  CD-
MOFs for drug delivery purposes. However, 
these particles disassembled in aqueous media, 
which limits their application for oral and 
intravenous administration.  
Surface modification is therefore necessary to 
improve their stability in water. The drug loaded 
CD-MOF nanocrystals (~ 650 nm) were 
successfully embedded in polyacrylic acid 
(PAA) polymer matrices. The composite 
microspheres exhibited spherical shapes and 
sustained drug release over a prolonged period 
of time (over 48 h). Drug loaded MOF/PAA 
composite microspheres were not toxic in vitro 
(cell viability ~ 90%) even at very high 
concentrations up to 17.5 mg/mL. MOF/PAA 
composite microspheres constitute an efficient 
and pharmaceutically acceptable MOF-based 
carrier for sustained drug release. However, the 
process of surface modification was 
complicated and lead to larger particles and 
reduced drug payloads. 
Water-stable MOFs are a novel type of hybrid 
particles, showing a high potential as drug 
carriers. Iron trimesate MOFs, namely, MIL-
100 (Fe) (MIL stands for Material of Institute 
Lavoisier) was among the first nano-scaled 
MOFs used for drug delivery. These particles 
were stable in water but degraded in phosphate 
buffer saline (PBS) losing their crystallinity and 
constitutive trimesate linkers. However, it was 
discovered that they kept their morphology 
intact. A thorough analysis based on Raman 
microscopy was carried on to gain insights on 
both the morphology and chemical composition 
of individual particles. It was evidenced the 
formation of a sharp erosion front during 
particle degradation. Noteworthy, the MOFs did 
not degrade during drug loading nor surface 
modification.  
Co-encapsulation of two synergic antibiotics 
(amoxicillin and potassium clavulanate) in MIL-
100 (Fe) nanoMOFs was achieved following a 
“green” procedure by soaking nanoMOFs in 
aqueous solutions of both drugs. Molecular 
modelling showed that each drug preferentially 
located in a separate nanoMOF compartment. 
Surprisingly, nanoMOFs were prone to co-
localize with bacteria once internalized in 
infected macrophages. NanoMOFs acted 
synergistically with the entrapped drugs to kill 
intracellular S. aureus, in vitro. These results 
pave the way towards the design of engineered 
nanocarriers in which each component 
synergistically plays a role in fighting the 
disease. 
These studies unravel the potential of “cage” 
particles for efficient drug entrapment and 
controlled release and open numerous 
possibilities for applications. 
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Titre : Particules de type “cage” pour des applications biomédicales 
Mots clés : particule "cage"; MOF ; médicament; dégradation; antibiotique 
Résumé: Les systèmes à délivrance de 
médicaments sont des technologies conçues 
pour administrer des molécules actives de façon 
optimisée afin d’améliorer leurs effets 
thérapeutiques tout en minimisant les effets 
secondaires. En effet, ces systèmes permettent 
une libération au niveau d’une cible 
thérapeutique. Les particules de type «cage» ont 
récemment attiré une attention particulière en 
raison de leur capacité accrue à (co)incorporer 
et à protéger des molécules actives vis-à-vis  de 
dégradations in vivo.  
Les cyclodextrines (CDs) sont des exemples 
type de molécules "cage", possédant une cavité 
hydrophobe et une surface extérieure 
hydrophile. Nous avons élaboré tout d’abord des 
assembages supramoléculaires à base de CDs 
d'environ 100 nm par une méthode douce 
consistant à mélanger deux solutions aqueuses 
de polymères neutres: 1) polymère de β-CD et 
2) dextrane greffé avec la benzophénone, 
molécule invitée formant des complexes 
d’inclusion avec les CDs. La procédure de 
préparation «verte» en une seule étape rend la 
formulation attractive, malgré sa relativement 
faible capacité d’encapsulation (5%pds). Afin 
d'améliorer cete charge, nous avons élaboré des 
particules hybrides organiques-inorganiques 
(MOFs) à base de CDs. Avantageusement, les 
CD-MOF comportent non seulement des cavités 
de CD, mais aussi de larges pores engendrés lors 
l’auto-assemblage de CDs. Le lansoprazole a été 
incorporé avec sucès (23%pds) dans les CD-
MOFs et nous avons montré que chaque CDs 
était capable d’accueillir une molécule de 
principe actif. Cependant, l’inconvénient majeur 
des CD-MOFs est leur faible stabilité en milieu 
aqueux, limitant leur domaine d’aplication. 
Une modification de surface est apparue donc 
nécessaire pour améliorer leur stabilité. Notre 
statégie a été d’incorporer les CD-MOFs dans 
des matrices d'acide polyacrylique (PAA). Des  
microsphères composites d’environ 650 nm ont 
été élaborées avec succès et ont permis une bone 
stabilité et une libération prolongée sur plus de 
48 h. Avantageusement, ces particules 
composites n’étaient pas toxiques in vitro même 
à des concentrations élevées.  
Ces microsphères apparaissent comme des 
systèmes efficaces pour assurer une bonne 
stabilité dans de milieux biologiques et une 
libération prolongée, mais leur synthèse est 
laborieuse et leur taille ne peut pas être réduite 
en dessus de 50nm. 
Ainsi, nous nous sommes orientés vers l’étude 
comparative de MOFs plus stables dans l’eau, à 
base de trimesate de fer. Les MIL-100 (Fe) 
(Material of Institute Lavoisier) figurent parmi 
les premiers MOF étudiés en tant que 
nanomédicaments (nanoMOFs). Ces particules, 
pafaitement stables dans l'eau, se dégradent dans 
des milieux contenant des phosphates (PBS) en 
perdant rapidement leur caractère cristallin et 
leurs ligands constitutifs. De façon étonnante, 
nous avons constaté que malgré leur 
dégradation, ces MOFs conservent leur taille 
intacte. Une analyse approfondie basée sur la 
microscopie de Raman a permis d’obtenir des 
informations pertinentes sur la morphologie et la 
composition chimique de particules 
individuelles. Ainsi, il a été montré qu’un front 
d'érosion délimitait nettement un coeur intact et 
une coquillé inorganique érodée. Cependant, ni 
l’encapsulation ni la modification de surface des 
MOFs n’altérait leur intégrité. Enfin, nous avons 
étudié la co-encapsulation de deux molécules 
actives utilisées en combinaison (amoxicilline et 
clavulanate de potassium) dans les nanoMOFs 
stables à base de MIL-100 (Fe). Les 
antibiotiques ont été incorporées par 
imprégnation et chaque molécule s’est localisée 
preferentiellement dans un compartiment (large 
ou petite cage) corroborant parfaitement les 
simulations par modélisation moléculaire. De 
plus, il a été découvert, de manière surprenante, 
qu’un grand nombre de nanoMOFs se localisait 
au voisinage des bactéries (S.aureus) dans des 
cellules infectées. En se dégradant dans ces 
cellules, les nanoMOFs contenant les 
antibiotiques ont réduit de manière importante la 
charge bactérienne intracellulaire. 
Ces études révèlent le potentiel des particules de 
type «cage» pour une incorporation efficace de 
molécules actives et leur libération contrôlée et 
ouvrent de nombreuses possibilités 
d’application. 
 
